[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Lopinavir.]
[G03XB02, ulipristal, The serum concentration of Ulipristal can be decreased when it is combined with Lopinavir.]
[J01GA01, streptomycin, Lopinavir may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The serum concentration of Antithymocyte immunoglobulin (rabbit) can be increased when it is combined with Lopinavir.]
[L01AD04, streptozocin, The serum concentration of Streptozocin can be increased when it is combined with Lopinavir.]
[L04AA27, fingolimod, The serum concentration of Fingolimod can be increased when it is combined with Lopinavir.]
[A02BX02, sucralfate, Lopinavir may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Lopinavir may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The metabolism of Sulfadiazine can be decreased when combined with Lopinavir.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Lopinavir.]
[M04AB02, sulfinpyrazone, The metabolism of Sulfinpyrazone can be decreased when combined with Lopinavir.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Lopinavir.]
[M01AB02, sulindac, The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Lopinavir.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Sulpiride.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Lopinavir.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Lopinavir.]
[M01AX04, apazone, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Azapropazone.]
[L01BB02, mercaptopurine, The serum concentration of Mercaptopurine can be increased when it is combined with Lopinavir.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Lopinavir.]
[N05CD07, temazepam, Lopinavir may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[L01CB02, teniposide, The serum concentration of Teniposide can be increased when it is combined with Lopinavir.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lopinavir.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Lopinavir.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Lopinavir.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Tetrabenazine.]
[S03AA02, tetracycline, The metabolism of Tetracycline can be decreased when combined with Lopinavir.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Ceftaroline fosamil.]
[N05AE05, lurasidone, The serum concentration of Lurasidone can be increased when it is combined with Lopinavir.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Lopinavir.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Lopinavir.]
[L04AX02, thalidomide, The serum concentration of Thalidomide can be increased when it is combined with Lopinavir.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Lopinavir.]
[P02CA02, thiabendazole, Lopinavir may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[L01XX41, eribulin, The serum concentration of Eribulin can be increased when it is combined with Lopinavir.]
[R06AD03, thiethylperazine, Lopinavir may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[L01AC01, thiotepa, The serum concentration of Thiotepa can be increased when it is combined with Lopinavir.]
[L01BB03, thioguanine, The serum concentration of Tioguanine can be increased when it is combined with Lopinavir.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Thiothixene.]
[G04BE06, moxisylyte, Lopinavir may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Lopinavir may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Lopinavir may decrease the excretion rate of Ticlopidine which could result in a higher serum level.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Lopinavir.]
[P01AB02, tinidazole, The metabolism of Tinidazole can be decreased when combined with Lopinavir.]
[S01AA12, tobramycin, Lopinavir may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Lopinavir.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lopinavir.]
[M02AA21, tolmetin, The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Lopinavir.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Lopinavir.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Lopinavir.]
[L01XF01, tretinoin, The serum concentration of Tretinoin can be increased when it is combined with Lopinavir.]
[S01BA05, triamcinolone, The serum concentration of Triamcinolone can be increased when it is combined with Lopinavir.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Lopinavir.]
[N05CD05, triazolam, The serum concentration of Triazolam can be increased when it is combined with Lopinavir.]
[A16AX12, trientine, Lopinavir may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, The serum concentration of Trifluridine can be increased when it is combined with Lopinavir.]
[S01BA09, clobetasone, The serum concentration of Clobetasone can be increased when it is combined with Lopinavir.]
[S01BA10, alclometasone, The serum concentration of Alclometasone can be increased when it is combined with Lopinavir.]
[D07AC02, fluclorolone, The serum concentration of Fluclorolone can be increased when it is combined with Lopinavir.]
[R03BA07, mometasone, The serum concentration of Mometasone can be increased when it is combined with Lopinavir.]
[A03AA05, trimebutine, The metabolism of Trimebutine can be decreased when combined with Lopinavir.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Lopinavir.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Lopinavir.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Lopinavir.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Lopinavir.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Lopinavir.]
[J01FA08, troleandomycin, The metabolism of Troleandomycin can be decreased when combined with Lopinavir.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Lopinavir.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Lopinavir.]
[L04AA26, belimumab, The serum concentration of Belimumab can be increased when it is combined with Lopinavir.]
[L01FX04, ipilimumab, Lopinavir may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Lopinavir.]
[R02AA14, oxyquinoline, Lopinavir may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Abiraterone can be decreased when combined with Lopinavir.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be decreased when combined with Lopinavir.]
[J05AP03, boceprevir, The serum concentration of Lopinavir can be decreased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Telaprevir can be decreased when combined with Lopinavir.]
[S01AA28, vancomycin, Lopinavir may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[L04AA28, belatacept, The serum concentration of Belatacept can be increased when it is combined with Lopinavir.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Ezogabine.]
[B01AF01, rivaroxaban, The serum concentration of Rivaroxaban can be increased when it is combined with Lopinavir.]
[R03AC18, indacaterol, The metabolism of Indacaterol can be decreased when combined with Lopinavir.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Lopinavir.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Lopinavir.]
[N06AX09, viloxazine, The metabolism of Lopinavir can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Lopinavir.]
[C04AX07, vincamine, The serum concentration of Vincamine can be increased when it is combined with Lopinavir.]
[L01CA02, vincristine, The serum concentration of Vincristine can be increased when it is combined with Lopinavir.]
[L01CA03, vindesine, The serum concentration of Vindesine can be increased when it is combined with Lopinavir.]
[B03BA01, vitamin B12, Lopinavir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.]
[A11HA03, vitamin E, The metabolism of Vitamin E can be decreased when combined with Lopinavir.]
[B01AA03, warfarin, The metabolism of Warfarin can be decreased when combined with Lopinavir.]
[J05AF01, zidovudine, The serum concentration of Zidovudine can be decreased when it is combined with Lopinavir.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Lopinavir.]
[J05AE02, indinavir, The serum concentration of Indinavir can be increased when it is combined with Lopinavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lopinavir.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Lopinavir.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Lopinavir.]
[M05BA05, tiludronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lopinavir is combined with Tiludronic acid.]
[B06AC02, icatibant, Lopinavir may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Lopinavir.]
[R03DC01, zafirlukast, The metabolism of Zafirlukast can be decreased when combined with Lopinavir.]
[A02BC04, rabeprazole, Rabeprazole can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lopinavir is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Ziprasidone.]
[G03AC10, drospirenone, The serum concentration of Drospirenone can be decreased when it is combined with Lopinavir.]
[V03AC02, deferiprone, Lopinavir may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[L04AA34, alemtuzumab, The serum concentration of Alemtuzumab can be increased when it is combined with Lopinavir.]
[N02BA01, aspirin, The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Lopinavir.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Lopinavir.]
[G04BD07, tolterodine, The serum concentration of Tolterodine can be increased when it is combined with Lopinavir.]
[J01DH04, doripenem, Lopinavir may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[L03AB11, peginterferon alfa-2a, The serum concentration of Peginterferon alfa-2a can be increased when it is combined with Lopinavir.]
[L01FA01, rituximab, The serum concentration of Rituximab can be increased when it is combined with Lopinavir.]
[J02AC03, voriconazole, The serum concentration of Voriconazole can be decreased when it is combined with Lopinavir.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Atropine.]
[M01CB03, auranofin, Lopinavir may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Lopinavir.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Lopinavir.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Lopinavir.]
[H02AB11, prednylidene, The serum concentration of Prednylidene can be increased when it is combined with Lopinavir.]
[B03XA04, peginesatide, Lopinavir may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, The serum concentration of Azacitidine can be increased when it is combined with Lopinavir.]
[L04AX01, azathioprine, The serum concentration of Azathioprine can be increased when it is combined with Lopinavir.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Lopinavir.]
[J01DF01, aztreonam, Lopinavir may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Lopinavir.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Lopinavir.]
[M03BX01, baclofen, Lopinavir may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Lopinavir.]
[L01FX02, gemtuzumab ozogamicin, The serum concentration of Gemtuzumab ozogamicin can be increased when it is combined with Lopinavir.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Lopinavir.]
[G04BD12, mirabegron, The metabolism of Mirabegron can be decreased when combined with Lopinavir.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be increased when it is combined with Lopinavir.]
[V03AX03, cobicistat, The metabolism of Cobicistat can be decreased when combined with Lopinavir.]
[J05AJ02, elvitegravir, The metabolism of Elvitegravir can be decreased when combined with Lopinavir.]
[L02BB04, enzalutamide, The serum concentration of Lopinavir can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Lopinavir.]
[L04AA31, teriflunomide, The serum concentration of Teriflunomide can be increased when it is combined with Lopinavir.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA22, abetimus, The serum concentration of Abetimus can be increased when it is combined with Lopinavir.]
[H02AA01, aldosterone, The serum concentration of Aldosterone can be increased when it is combined with Lopinavir.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Lopinavir.]
[D02BA02, octinoxate, Lopinavir may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The serum concentration of Lopinavir can be decreased when it is combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Lopinavir.]
[N04BD02, rasagiline, Lopinavir may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C08CA13, lercanidipine, The metabolism of Lercanidipine can be decreased when combined with Lopinavir.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Lopinavir.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Lopinavir.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Lopinavir.]
[G04BD10, darifenacin, The metabolism of Darifenacin can be decreased when combined with Lopinavir.]
[V09IX04, fluorodeoxyglucose F18, Lopinavir may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Lopinavir.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Pasireotide.]
[G04BE03, sildenafil, The serum concentration of Sildenafil can be increased when it is combined with Lopinavir.]
[V08CA11, gadofosveset, Lopinavir may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Lopinavir.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Lopinavir.]
[A16AX08, teduglutide, Lopinavir may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The serum concentration of Lomitapide can be increased when it is combined with Lopinavir.]
[J04AK05, bedaquiline, The metabolism of Bedaquiline can be decreased when combined with Lopinavir.]
[C04AX11, bencyclane, The metabolism of Bencyclane can be decreased when combined with Lopinavir.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Lopinavir.]
[A16AX09, glycerol phenylbutyrate, Lopinavir may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Lopinavir.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Lopinavir.]
[N02BA10, benorilate, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Benorilate.]
[A10BK02, canagliflozin, The metabolism of Canagliflozin can be decreased when combined with Lopinavir.]
[L04AX07, dimethyl fumarate, The serum concentration of Dimethyl fumarate can be increased when it is combined with Lopinavir.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Moxifloxacin.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Lopinavir.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Lopinavir.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Lopinavir.]
[J02AX04, caspofungin, The excretion of Caspofungin can be decreased when combined with Lopinavir.]
[L03AA12, ancestim, Lopinavir may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Lopinavir.]
[L04AA18, everolimus, The serum concentration of Everolimus can be increased when it is combined with Lopinavir.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Lopinavir.]
[L01EC02, dabrafenib, The serum concentration of Dabrafenib can be increased when it is combined with Lopinavir.]
[R02AX03, benzydamine, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Benzydamine.]
[L01EE01, trametinib, Lopinavir may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[V09AX05, florbetapir F-18, Lopinavir may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Lopinavir.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Lopinavir.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Lopinavir.]
[C08EA02, bepridil, The metabolism of Bepridil can be decreased when combined with Lopinavir.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Lopinavir.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Lopinavir.]
[A05AA03, cholic acid, The excretion of Cholic Acid can be decreased when combined with Lopinavir.]
[C02KX04, macitentan, The metabolism of Macitentan can be decreased when combined with Lopinavir.]
[L01EL01, ibrutinib, The serum concentration of Ibrutinib can be increased when it is combined with Lopinavir.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Lopinavir.]
[G03AC08, etonogestrel, The serum concentration of Etonogestrel can be decreased when it is combined with Lopinavir.]
[J05AP05, simeprevir, The serum concentration of Simeprevir can be increased when it is combined with Lopinavir.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Lopinavir.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Lopinavir.]
[C01CA27, droxidopa, Lopinavir may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Lopinavir.]
[A16AA07, metreleptin, The metabolism of Lopinavir can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The serum concentration of Apremilast can be increased when it is combined with Lopinavir.]
[L02BG02, formestane, Lopinavir may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The serum concentration of Betamethasone can be increased when it is combined with Lopinavir.]
[V03AB34, fomepizole, Lopinavir may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C10AB02, bezafibrate, The metabolism of Bezafibrate can be decreased when combined with Lopinavir.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Lopinavir.]
[L04AC11, siltuximab, The serum concentration of Siltuximab can be increased when it is combined with Lopinavir.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Lopinavir.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Lopinavir.]
[L04AA33, vedolizumab, The serum concentration of Vedolizumab can be increased when it is combined with Lopinavir.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Lopinavir.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Lopinavir.]
[L01XH04, belinostat, The serum concentration of Belinostat can be increased when it is combined with Lopinavir.]
[L01EM01, idelalisib, The serum concentration of Idelalisib can be increased when it is combined with Lopinavir.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lopinavir.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, The serum concentration of Peginterferon beta-1a can be increased when it is combined with Lopinavir.]
[V08AA01, diatrizoic acid, Lopinavir may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[V08AA04, iothalamic acid, Lopinavir may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be decreased when combined with Lopinavir.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Lopinavir.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Dihydrostreptomycin.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lopinavir.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Lopinavir.]
[L01BC08, decitabine, The serum concentration of Decitabine can be increased when it is combined with Lopinavir.]
[A11HA08, tocophersolan, The metabolism of Tocofersolan can be decreased when combined with Lopinavir.]
[L04AX05, pirfenidone, The serum concentration of Pirfenidone can be increased when it is combined with Lopinavir.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Lopinavir.]
[S03AA06, gentamicin, Lopinavir may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01FX07, blinatumomab, The serum concentration of Blinatumomab can be increased when it is combined with Lopinavir.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Lopinavir.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Lopinavir.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be decreased when combined with Lopinavir.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Lopinavir.]
[N06AX11, mirtazapine, The metabolism of Mirtazapine can be decreased when combined with Lopinavir.]
[L04AC10, secukinumab, The serum concentration of Secukinumab can be increased when it is combined with Lopinavir.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Lopinavir.]
[L01EX08, lenvatinib, The serum concentration of Lenvatinib can be increased when it is combined with Lopinavir.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Lopinavir.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Lopinavir.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Lopinavir.]
[L01DC01, bleomycin, The serum concentration of Bleomycin can be increased when it is combined with Lopinavir.]
[C01EB17, ivabradine, The metabolism of Ivabradine can be decreased when combined with Lopinavir.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Lopinavir.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Lopinavir.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Lopinavir.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Lopinavir.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Lopinavir.]
[A04AD14, rolapitant, The metabolism of Rolapitant can be decreased when combined with Lopinavir.]
[G02CX02, flibanserin, The metabolism of Flibanserin can be decreased when combined with Lopinavir.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AX15, cariprazine, The metabolism of Cariprazine can be decreased when combined with Lopinavir.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Lopinavir.]
[M02AA25, aceclofenac, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Acemetacin.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Lopinavir.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Lopinavir.]
[V03AB37, idarucizumab, Lopinavir may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Lopinavir.]
[R03DX09, mepolizumab, The serum concentration of Mepolizumab can be increased when it is combined with Lopinavir.]
[J02AC05, isavuconazole, The serum concentration of Isavuconazole can be increased when it is combined with Lopinavir.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Lopinavir.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lopinavir.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Lopinavir.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Lopinavir.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Lopinavir.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Lopinavir.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lopinavir.]
[G04CA01, alfuzosin, The serum concentration of Alfuzosin can be increased when it is combined with Lopinavir.]
[M04AB05, lesinurad, Lopinavir may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Lopinavir.]
[J05AP11, grazoprevir, The metabolism of Grazoprevir can be decreased when combined with Lopinavir.]
[M01AE16, alminoprofen, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Alminoprofen.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Lopinavir.]
[L04AC13, ixekizumab, The serum concentration of Ixekizumab can be increased when it is combined with Lopinavir.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Lopinavir.]
[N05BA08, bromazepam, Lopinavir may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The serum concentration of Bromocriptine can be increased when it is combined with Lopinavir.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[D07AC11, amcinonide, The serum concentration of Amcinonide can be increased when it is combined with Lopinavir.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lopinavir.]
[C08CA01, amlodipine, The serum concentration of Amlodipine can be increased when it is combined with Lopinavir.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Lopinavir.]
[C03CA02, bumetanide, The risk or severity of nephrotoxicity can be increased when Bumetanide is combined with Lopinavir.]
[N01BB01, bupivacaine, The metabolism of Bupivacaine can be decreased when combined with Lopinavir.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Lopinavir.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Buserelin.]
[N05BE01, buspirone, The metabolism of Buspirone can be decreased when combined with Lopinavir.]
[L01AB01, busulfan, The serum concentration of Busulfan can be increased when it is combined with Lopinavir.]
[L01XX27, arsenic trioxide, The serum concentration of Arsenic trioxide can be increased when it is combined with Lopinavir.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Lopinavir.]
[M02AA03, clofezone, Rabeprazole can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Lopinavir.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Lopinavir.]
[L01XK03, rucaparib, The metabolism of Rucaparib can be decreased when combined with Lopinavir.]
[L04AC12, brodalumab, The serum concentration of Brodalumab can be increased when it is combined with Lopinavir.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be decreased when combined with Lopinavir.]
[A07EC04, balsalazide, The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Lopinavir.]
[L04AA36, ocrelizumab, The serum concentration of Ocrelizumab can be increased when it is combined with Lopinavir.]
[A06AH05, naldemedine, Lopinavir may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Lopinavir.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Lopinavir.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Lopinavir.]
[D05AX03, calcitriol, The metabolism of Calcitriol can be decreased when combined with Lopinavir.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[P01CA02, benznidazole, Lopinavir may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[L04AC01, daclizumab, The serum concentration of Daclizumab can be increased when it is combined with Lopinavir.]
[J01XX08, linezolid, The serum concentration of Linezolid can be increased when it is combined with Lopinavir.]
[J05AF06, abacavir, The serum concentration of Abacavir can be decreased when it is combined with Lopinavir.]
[J05AE09, tipranavir, The serum concentration of Lopinavir can be decreased when it is combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Lopinavir.]
[L04AB02, infliximab, The serum concentration of Infliximab can be increased when it is combined with Lopinavir.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be decreased when combined with Lopinavir.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Lopinavir.]
[N04BD03, safinamide, The metabolism of Safinamide can be decreased when combined with Lopinavir.]
[L04AC14, sarilumab, The serum concentration of Sarilumab can be increased when it is combined with Lopinavir.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Delafloxacin.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Lopinavir.]
[L04AC16, guselkumab, The serum concentration of Guselkumab can be increased when it is combined with Lopinavir.]
[L01BC06, capecitabine, The serum concentration of Capecitabine can be increased when it is combined with Lopinavir.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Lopinavir.]
[L01EH02, neratinib, The serum concentration of Neratinib can be increased when it is combined with Lopinavir.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lopinavir.]
[L01XH01, vorinostat, The serum concentration of Vorinostat can be increased when it is combined with Lopinavir.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Lopinavir.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Lopinavir.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AB07, bisoprolol, The metabolism of Bisoprolol can be decreased when combined with Lopinavir.]
[J05AG03, efavirenz, The metabolism of Lopinavir can be increased when combined with Efavirenz.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The serum concentration of Antilymphocyte immunoglobulin (horse) can be increased when it is combined with Lopinavir.]
[S01AA13, fusidic acid, The metabolism of Fusidic acid can be decreased when combined with Lopinavir.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Pipemidic acid.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Lopinavir.]
[L04AC02, basiliximab, The serum concentration of Basiliximab can be increased when it is combined with Lopinavir.]
[L01BA03, raltitrexed, The serum concentration of Raltitrexed can be increased when it is combined with Lopinavir.]
[N05CD09, brotizolam, The metabolism of Brotizolam can be decreased when combined with Lopinavir.]
[R03BA02, budesonide, The serum concentration of Budesonide can be increased when it is combined with Lopinavir.]
[M01AB07, bumadizone, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Lopinavir.]
[J05AX18, letermovir, The excretion of Letermovir can be decreased when combined with Lopinavir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Butriptyline.]
[C01AA02, acetyldigoxins, Lopinavir may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Lopinavir.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Lopinavir.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Acrivastine.]
[V04CD06, macimorelin, The metabolism of Macimorelin can be decreased when combined with Lopinavir.]
[L02BB05, apalutamide, The serum concentration of Lopinavir can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Lopinavir can be decreased when it is combined with Carbamazepine.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, The serum concentration of Interferon alfa-n1 can be increased when it is combined with Lopinavir.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Lopinavir.]
[B02BX09, fostamatinib, The serum concentration of R406, an active metabolite of Fostamatinib, can be increased when used in combination with Lopinavir.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Lopinavir.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Lopinavir.]
[L04AA37, baricitinib, The serum concentration of Baricitinib can be increased when it is combined with Lopinavir.]
[V03AE10, sodium zirconium cyclosilicate, Sodium zirconium cyclosilicate can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Cefepime is combined with Lopinavir.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Lopinavir.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Lopinavir.]
[L01EC03, encorafenib, The serum concentration of Encorafenib can be increased when it is combined with Lopinavir.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Lopinavir.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity can be increased when Ceftibuten is combined with Lopinavir.]
[J01GB14, plazomicin, Lopinavir may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Celiprolol.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Lopinavir.]
[L01XX62, ivosidenib, The serum concentration of Ivosidenib can be increased when it is combined with Lopinavir.]
[A16AX14, migalastat, Lopinavir may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Lopinavir can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Lopinavir.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Lopinavir.]
[J01AA13, eravacycline, The metabolism of Eravacycline can be decreased when combined with Lopinavir.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Lopinavir.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Lopinavir.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Lopinavir.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Lopinavir.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Lopinavir.]
[D08AE05, chloroxylenol, Lopinavir may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Inotersen.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Lopinavir.]
[R03BB08, revefenacin, Lopinavir may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Lopinavir.]
[L04AA39, emapalumab, The serum concentration of Emapalumab can be increased when it is combined with Lopinavir.]
[L01AD01, carmustine, The serum concentration of Carmustine can be increased when it is combined with Lopinavir.]
[L01EX12, larotrectinib, The metabolism of Larotrectinib can be decreased when combined with Lopinavir.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be decreased when combined with Lopinavir.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Lopinavir.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Amifampridine.]
[L04AA43, ravulizumab, The serum concentration of Ravulizumab can be increased when it is combined with Lopinavir.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Lopinavir.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Cibenzoline.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Lopinavir.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Lopinavir.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Lopinavir.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Lopinavir is combined with Siponimod.]
[J01FA09, clarithromycin, The serum concentration of Clarithromycin can be increased when it is combined with Lopinavir.]
[N06BA14, solriamfetol, Lopinavir may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Lopinavir.]
[N05BA09, clobazam, The metabolism of Clobazam can be decreased when combined with Lopinavir.]
[D07AB21, clocortolone, The serum concentration of Clocortolone can be increased when it is combined with Lopinavir.]
[H02AB14, cloprednol, The serum concentration of Cloprednol can be increased when it is combined with Lopinavir.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Lopinavir.]
[L04AB01, etanercept, The serum concentration of Etanercept can be increased when it is combined with Lopinavir.]
[H02AB17, cortivazol, The serum concentration of Cortivazol can be increased when it is combined with Lopinavir.]
[L04AC18, risankizumab, The serum concentration of Risankizumab can be increased when it is combined with Lopinavir.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Lopinavir.]
[L01FX14, polatuzumab vedotin, The risk or severity of adverse effects can be increased when Lopinavir is combined with Polatuzumab vedotin.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Lopinavir.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Cefadroxil is combined with Lopinavir.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Lopinavir.]
[L01XX66, selinexor, The metabolism of Selinexor can be decreased when combined with Lopinavir.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Cefatrizine.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity can be increased when Cefazolin is combined with Lopinavir.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Lopinavir.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Lopinavir.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Lopinavir.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Lopinavir.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Lopinavir.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Lopinavir.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Lopinavir.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Lopinavir.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Lopinavir.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Lopinavir.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Cicletanine.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Lopinavir.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Lopinavir.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Lopinavir.]
[M03BX08, cyclobenzaprine, The metabolism of Cyclobenzaprine can be decreased when combined with Lopinavir.]
[L04AA44, upadacitinib, The serum concentration of Upadacitinib can be increased when it is combined with Lopinavir.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Lopinavir.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Lopinavir.]
[N07XX11, pitolisant, The serum concentration of Lopinavir can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The serum concentration of Pretomanid can be increased when it is combined with Lopinavir.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Lopinavir.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Lopinavir.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Lopinavir.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Lopinavir.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Lopinavir.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Lopinavir.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Cefaloridine.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Lopinavir.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Lopinavir.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity can be increased when Cefradine is combined with Lopinavir.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be increased when it is combined with Lopinavir.]
[G03DB05, demegestone, The serum concentration of Demegestone can be decreased when it is combined with Lopinavir.]
[L01FD01, trastuzumab, The serum concentration of Trastuzumab can be increased when it is combined with Lopinavir.]
[N02CC08, lasmiditan, The serum concentration of Lasmiditan can be increased when it is combined with Lopinavir.]
[L04AX09, diroximel fumarate, The serum concentration of Diroximel fumarate can be increased when it is combined with Lopinavir.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Lopinavir.]
[G03AC09, desogestrel, The serum concentration of Desogestrel can be decreased when it is combined with Lopinavir.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Lopinavir.]
[N03AX25, cenobamate, The serum concentration of Lopinavir can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Givosiran.]
[M09AX08, golodirsen, Lopinavir may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Lopinavir.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lopinavir.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lopinavir.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Lopinavir may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Lopinavir.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Lopinavir.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Lopinavir.]
[L04AA53, teprotumumab, The serum concentration of Teprotumumab can be increased when it is combined with Lopinavir.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be increased when it is combined with Lopinavir.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be decreased when combined with Lopinavir.]
[C10AX15, bempedoic acid, The excretion of Bempedoic acid can be decreased when combined with Lopinavir.]
[J05AB16, remdesivir, The metabolism of Remdesivir can be decreased when combined with Lopinavir.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Lopinavir.]
[H02CA02, osilodrostat, The serum concentration of Osilodrostat can be increased when it is combined with Lopinavir.]
[J05AE05, amprenavir, The serum concentration of Lopinavir can be decreased when it is combined with Amprenavir.]
[L04AA38, ozanimod, The serum concentration of Ozanimod can be increased when it is combined with Lopinavir.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Lopinavir.]
[R02AA03, dichlorobenzyl alcohol, Lopinavir may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The serum concentration of Dienogest can be decreased when it is combined with Lopinavir.]
[D07AC19, difluprednate, The serum concentration of Difluprednate can be increased when it is combined with Lopinavir.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Lopinavir.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Lopinavir.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be decreased when combined with Lopinavir.]
[L01XF03, bexarotene, The serum concentration of Bexarotene can be increased when it is combined with Lopinavir.]
[C08CA16, clevidipine, The serum concentration of Clevidipine can be increased when it is combined with Lopinavir.]
[C01BD07, dronedarone, The serum concentration of Dronedarone can be increased when it is combined with Lopinavir.]
[L01AA02, chlorambucil, The serum concentration of Chlorambucil can be increased when it is combined with Lopinavir.]
[S03AA08, chloramphenicol, The serum concentration of Chloramphenicol can be increased when it is combined with Lopinavir.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Chlorcyclizine.]
[L01EN02, pemigatinib, The metabolism of Pemigatinib can be decreased when combined with Lopinavir.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Lopinavir.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be increased when it is combined with Lopinavir.]
[D07XB03, fluprednidene, The serum concentration of Fluprednidene can be increased when it is combined with Lopinavir.]
[M01AC04, droxicam, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Droxicam.]
[L01EX19, ripretinib, The serum concentration of Ripretinib can be increased when it is combined with Lopinavir.]
[V08CA05, mangafodipir, Lopinavir may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be increased when it is combined with Lopinavir.]
[M02AA27, dexketoprofen, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Lopinavir.]
[L04AA47, inebilizumab, The serum concentration of Inebilizumab can be increased when it is combined with Lopinavir.]
[L01XX69, lurbinectedin, The serum concentration of Lurbinectedin can be increased when it is combined with Lopinavir.]
[R05CB11, stepronin, The serum concentration of Stepronin can be increased when it is combined with Lopinavir.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Lopinavir.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Lopinavir.]
[J05AX29, fostemsavir, The metabolism of Fostemsavir can be decreased when combined with Lopinavir.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Lopinavir.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Lopinavir.]
[L04AC19, satralizumab, The serum concentration of Lopinavir can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be increased when it is combined with Lopinavir.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Lopinavir.]
[L01EX23, pralsetinib, The serum concentration of Pralsetinib can be increased when it is combined with Lopinavir.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Lopinavir.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be decreased when combined with Lopinavir.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lopinavir.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Lopinavir.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Lopinavir.]
[A11CC05, cholecalciferol, The metabolism of Cholecalciferol can be decreased when combined with Lopinavir.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Lopinavir.]
[N02BA07, ethenzamide, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Ethenzamide.]
[N02BA03, choline salicylate, Lopinavir may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The metabolism of Vinpocetine can be decreased when combined with Lopinavir.]
[G03DC06, ethynodiol, The serum concentration of Etynodiol can be decreased when it is combined with Lopinavir.]
[M01AB08, etodolac, The risk or severity of nephrotoxicity can be increased when Etodolac is combined with Lopinavir.]
[M02AA06, etofenamate, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Etofenamate.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Lopinavir.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be decreased when combined with Lopinavir.]
[L01BB05, fludarabine, The serum concentration of Fludarabine can be increased when it is combined with Lopinavir.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Lopinavir.]
[M01AX25, chondroitin sulfates, Lopinavir may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L04AD03, voclosporin, The metabolism of Voclosporin can be decreased when combined with Lopinavir.]
[P03AX07, abametapir, The serum concentration of Lopinavir can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Lopinavir.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Lopinavir.]
[N03AX10, felbamate, The metabolism of Felbamate can be decreased when combined with Lopinavir.]
[M01AE05, fenbufen, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Fenbufen.]
[C01CA19, fenoldopam, Lopinavir may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Lopinavir.]
[J01DD15, cefdinir, Lopinavir may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Flumequine.]
[R03BA03, flunisolide, The serum concentration of Flunisolide can be increased when it is combined with Lopinavir.]
[S02BA08, fluocinolone acetonide, The serum concentration of Fluocinolone acetonide can be increased when it is combined with Lopinavir.]
[N02BG07, flupirtine, Lopinavir may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Lopinavir.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Lopinavir.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Lopinavir.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Lopinavir.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Peginterferon alfa-2b can be increased when it is combined with Lopinavir.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Lopinavir.]
[A02BA01, cimetidine, Cimetidine can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V08CA04, gadoteridol, Lopinavir may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Lopinavir.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Lopinavir can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Lopinavir.]
[S03AA07, ciprofloxacin, The metabolism of Lopinavir can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The serum concentration of Cisplatin can be increased when it is combined with Lopinavir.]
[N06AB04, citalopram, The metabolism of Citalopram can be decreased when combined with Lopinavir.]
[L04AA54, pegcetacoplan, The serum concentration of Pegcetacoplan can be increased when it is combined with Lopinavir.]
[J02AX07, ibrexafungerp, The serum concentration of Ibrexafungerp can be increased when it is combined with Lopinavir.]
[C03DA05, finerenone, The serum concentration of the active metabolites of Finerenone can be increased when Finerenone is used in combination with Lopinavir.]
[L04AA48, belumosudil, The serum concentration of Belumosudil can be increased when it is combined with Lopinavir.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Lopinavir is combined with Fexinidazole.]
[L04AA51, anifrolumab, The serum concentration of Anifrolumab can be increased when it is combined with Lopinavir.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Mobocertinib.]
[L01FX23, tisotumab vedotin, The metabolism of Tisotumab vedotin can be decreased when combined with Lopinavir.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Lopinavir.]
[L04AA59, avacopan, The metabolism of Avacopan can be decreased when combined with Lopinavir.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Clemastine.]
[M01AG01, mefenamic acid, The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Lopinavir.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Lopinavir.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Lopinavir.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Lopinavir.]
[N06AX25, St. John's wort extract, The serum concentration of Lopinavir can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Asciminib can be increased when it is combined with Lopinavir.]
[L02BG06, exemestane, The metabolism of Exemestane can be decreased when combined with Lopinavir.]
[J05AX10, maribavir, The metabolism of Maribavir can be decreased when combined with Lopinavir.]
[L03AB15, ropeginterferon alfa-2b, The serum concentration of Ropeginterferon alfa-2b can be increased when it is combined with Lopinavir.]
[D07AD01, clobetasol, The serum concentration of Clobetasol can be increased when it is combined with Lopinavir.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Lopinavir.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Lopinavir.]
[C10AB01, clofibrate, The metabolism of Clofibrate can be decreased when combined with Lopinavir.]
[B06AX04, mitapivat, The metabolism of Mitapivat can be decreased when combined with Lopinavir.]
[N01BB10, levobupivacaine, Lopinavir may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01EJ03, pacritinib, The serum concentration of Pacritinib can be increased when it is combined with Lopinavir.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Lopinavir.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Lopinavir.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be decreased when combined with Lopinavir.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Lopinavir.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Lopinavir.]
[C01EB24, mavacamten, The serum concentration of Mavacamten can be increased when it is combined with Lopinavir.]
[J05AH02, oseltamivir, Lopinavir may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Lopinavir.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Lopinavir.]
[L04AC22, spesolimab, The serum concentration of Spesolimab can be increased when it is combined with Lopinavir.]
[L04AA56, deucravacitinib, The serum concentration of Deucravacitinib can be increased when it is combined with Lopinavir.]
[A16AX21, elivaldogene autotemcel, The therapeutic efficacy of Elivaldogene autotemcel can be decreased when used in combination with Lopinavir.]
[N05BA21, clotiazepam, The metabolism of Clotiazepam can be decreased when combined with Lopinavir.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Lopinavir.]
[A04AA02, granisetron, The metabolism of Granisetron can be decreased when combined with Lopinavir.]
[L01XX77, adagrasib, The serum concentration of Adagrasib can be increased when it is combined with Lopinavir.]
[N05AH02, clozapine, The metabolism of Clozapine can be decreased when combined with Lopinavir.]
[L01EN04, futibatinib, The metabolism of Futibatinib can be decreased when combined with Lopinavir.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Lopinavir.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Lopinavir.]
[J01GB12, arbekacin, Lopinavir may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[D07AC12, halometasone, The serum concentration of Halometasone can be increased when it is combined with Lopinavir.]
[H01AC08, somatrogon, The metabolism of Lopinavir can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Cocaine.]
[M09AX11, palovarotene, The serum concentration of Palovarotene can be increased when it is combined with Lopinavir.]
[L04AC21, bimekizumab, The serum concentration of Bimekizumab can be increased when it is combined with Lopinavir.]
[M01AX13, proquazone, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Proquazone.]
[R05DA04, codeine, The metabolism of Codeine can be decreased when combined with Lopinavir.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Lopinavir.]
[J01XB01, colistin, Lopinavir may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Cefpirome.]
[L04AA13, leflunomide, The serum concentration of Leflunomide can be increased when it is combined with Lopinavir.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Lopinavir.]
[A04AA03, tropisetron, Lopinavir may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Lopinavir.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Lopinavir.]
[L01BB07, nelarabine, The serum concentration of Nelarabine can be increased when it is combined with Lopinavir.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Lopinavir.]
[J01FA15, telithromycin, The metabolism of Lopinavir can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The serum concentration of Ciclesonide can be increased when it is combined with Lopinavir.]
[B01AC10, indobufen, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Desloratadine.]
[J05AB14, valganciclovir, Lopinavir may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Lopinavir may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Lopinavir may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Lopinavir may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Lopinavir may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Lopinavir may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Lopinavir.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Lopinavir.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Lopinavir.]
[J02AC02, itraconazole, The metabolism of Itraconazole can be decreased when combined with Lopinavir.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Lopinavir.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Emedastine.]
[N05BA10, ketazolam, The metabolism of Ketazolam can be decreased when combined with Lopinavir.]
[M01AA06, kebuzone, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Imatinib can be increased when it is combined with Lopinavir.]
[J02AC04, posaconazole, The metabolism of Lopinavir can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Lopinavir.]
[C08CA09, lacidipine, The metabolism of Lacidipine can be decreased when combined with Lopinavir.]
[N03AX09, lamotrigine, The serum concentration of Lamotrigine can be decreased when it is combined with Lopinavir.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Lopinavir.]
[S01BA03, cortisone, The metabolism of Cortisone can be decreased when combined with Lopinavir.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Lonazolac.]
[R06AX13, loratadine, The metabolism of Loratadine can be decreased when combined with Lopinavir.]
[M02AA31, loxoprofen, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Loxoprofen.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Lopinavir.]
[C09AA03, lisinopril, Lopinavir may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA11, manidipine, The metabolism of Manidipine can be decreased when combined with Lopinavir.]
[S01BA08, medrysone, The serum concentration of Medrysone can be increased when it is combined with Lopinavir.]
[H02AB15, meprednisone, The serum concentration of Meprednisone can be increased when it is combined with Lopinavir.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Lopinavir.]
[J01DH02, meropenem, Lopinavir may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Adenosine.]
[C04AX01, cyclandelate, The metabolism of Cyclandelate can be decreased when combined with Lopinavir.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Lopinavir.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be decreased when combined with Lopinavir.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Melperone.]
[L04AA15, alefacept, The serum concentration of Alefacept can be increased when it is combined with Lopinavir.]
[J01FA03, midecamycin, The metabolism of Midecamycin can be decreased when combined with Lopinavir.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Lopinavir.]
[J05AF07, tenofovir disoproxil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Lopinavir.]
[L01AA01, cyclophosphamide, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Lopinavir.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be increased when it is combined with Lopinavir.]
[N06BA07, modafinil, The metabolism of Modafinil can be decreased when combined with Lopinavir.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Lopinavir.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Lopinavir.]
[C10AA07, rosuvastatin, The serum concentration of Rosuvastatin can be increased when it is combined with Lopinavir.]
[M02AA02, mofebutazone, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be decreased when combined with Lopinavir.]
[L01BC01, cytarabine, The serum concentration of Cytarabine can be increased when it is combined with Lopinavir.]
[G04BE09, vardenafil, The serum concentration of Vardenafil can be increased when it is combined with Lopinavir.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Lopinavir.]
[L01AX04, dacarbazine, The serum concentration of Dacarbazine can be increased when it is combined with Lopinavir.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Lopinavir.]
[G03XA01, danazol, The metabolism of Lopinavir can be decreased when combined with Danazol.]
[L01DB02, daunorubicin, The serum concentration of Daunorubicin can be increased when it is combined with Lopinavir.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Lopinavir.]
[M01AX01, nabumetone, The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Lopinavir.]
[N07BB05, nalmefene, Lopinavir may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Lopinavir.]
[S01GX04, nedocromil, Lopinavir may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Lopinavir can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Lopinavir may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Lopinavir may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[N03AG06, tiagabine, The metabolism of Tiagabine can be decreased when combined with Lopinavir.]
[G03DB04, nomegestrol, The serum concentration of Nomegestrol can be decreased when it is combined with Lopinavir.]
[B01AX05, fondaparinux, Lopinavir may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[D11AH02, pimecrolimus, The serum concentration of Pimecrolimus can be increased when it is combined with Lopinavir.]
[N06AB10, escitalopram, The metabolism of Escitalopram can be decreased when combined with Lopinavir.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Lopinavir.]
[A07EC03, olsalazine, The risk or severity of nephrotoxicity can be increased when Olsalazine is combined with Lopinavir.]
[H01BA02, desmopressin, Lopinavir may decrease the excretion rate of Desmopressin which could result in a higher serum level.]
[S01BA11, desonide, The serum concentration of Desonide can be increased when it is combined with Lopinavir.]
[D07XC02, desoximetasone, The serum concentration of Desoximetasone can be increased when it is combined with Lopinavir.]
[V04CH02, indigo carmine, Lopinavir may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Lopinavir may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[C09XA02, aliskiren, The metabolism of Aliskiren can be decreased when combined with Lopinavir.]
[L01XA03, oxaliplatin, The serum concentration of Oxaliplatin can be increased when it is combined with Lopinavir.]
[M01AE12, oxaprozin, The risk or severity of nephrotoxicity can be increased when Oxaprozin is combined with Lopinavir.]
[S03BA01, dexamethasone, The serum concentration of Dexamethasone can be increased when it is combined with Lopinavir.]
[G04BD04, oxybutynin, The metabolism of Oxybutynin can be decreased when combined with Lopinavir.]
[L04AB04, adalimumab, The serum concentration of Adalimumab can be increased when it is combined with Lopinavir.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Lopinavir.]
[N06BA02, dextroamphetamine, Lopinavir may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Lopinavir.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Lopinavir.]
[N06AB05, paroxetine, The metabolism of Paroxetine can be decreased when combined with Lopinavir.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Lopinavir.]
[C01DA05, pentaerythritol tetranitrate, Lopinavir may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[P03AC04, permethrin, Lopinavir may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The metabolism of Diazepam can be decreased when combined with Lopinavir.]
[R05DA08, pholcodine, Lopinavir may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lopinavir is combined with Clodronic acid.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Lopinavir.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Foscarnet.]
[A03AA07, dicyclomine, Lopinavir may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, The serum concentration of Didanosine can be decreased when it is combined with Lopinavir.]
[C02DG01, pinacidil, The metabolism of Pinacidil can be decreased when combined with Lopinavir.]
[A03AX04, pinaverium, The metabolism of Pinaverium can be decreased when combined with Lopinavir.]
[A10BG03, pioglitazone, The metabolism of Pioglitazone can be decreased when combined with Lopinavir.]
[L01DC04, ixabepilone, The serum concentration of Ixabepilone can be increased when it is combined with Lopinavir.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Lopinavir.]
[L01DB08, pirarubicin, The serum concentration of Pirarubicin can be increased when it is combined with Lopinavir.]
[L02AA01, diethylstilbestrol, The serum concentration of Diethylstilbestrol can be decreased when it is combined with Lopinavir.]
[C08CA03, isradipine, The serum concentration of Isradipine can be increased when it is combined with Lopinavir.]
[D07XC04, diflucortolone, The serum concentration of Difluocortolone can be increased when it is combined with Lopinavir.]
[N02BA11, diflunisal, The risk or severity of nephrotoxicity can be increased when Diflunisal is combined with Lopinavir.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Lopinavir.]
[C01AA05, digoxin, Lopinavir may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AX09, ezetimibe, The excretion of Ezetimibe can be decreased when combined with Lopinavir.]
[L01XX24, pegaspargase, The serum concentration of Pegaspargase can be increased when it is combined with Lopinavir.]
[C04AE04, dihydroergocristine, The serum concentration of Dihydroergocristine can be increased when it is combined with Lopinavir.]
[N02CA01, dihydroergotamine, The serum concentration of Dihydroergotamine can be increased when it is combined with Lopinavir.]
[N02AA03, hydromorphone, Lopinavir may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, The serum concentration of Lenalidomide can be increased when it is combined with Lopinavir.]
[J05AE08, atazanavir, The metabolism of Lopinavir can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Lopinavir.]
[H03BC01, potassium perchlorate, Lopinavir may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Lopinavir may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D07AC18, prednicarbate, The serum concentration of Prednicarbate can be increased when it is combined with Lopinavir.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Lopinavir.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Lopinavir may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Lopinavir may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N02BB04, propyphenazone, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Proglumetacin.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Lopinavir.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Lopinavir.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Lopinavir.]
[B01AC07, dipyridamole, The serum concentration of Dipyridamole can be increased when it is combined with Lopinavir.]
[A03FA02, cisapride, The serum concentration of Cisapride can be increased when it is combined with Lopinavir.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Lopinavir.]
[S01AX06, resorcinol, Lopinavir may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The metabolism of Disopyramide can be decreased when combined with Lopinavir.]
[L04AA23, natalizumab, The serum concentration of Natalizumab can be increased when it is combined with Lopinavir.]
[P03AA04, disulfiram, The metabolism of Disulfiram can be decreased when combined with Lopinavir.]
[S02AA12, rifamycin SV, The metabolism of Lopinavir can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The serum concentration of Lopinavir can be decreased when it is combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Lopinavir.]
[N05AX08, risperidone, The metabolism of Risperidone can be decreased when combined with Lopinavir.]
[R06AE09, levocetirizine, The metabolism of Levocetirizine can be decreased when combined with Lopinavir.]
[L04AA21, efalizumab, The serum concentration of Efalizumab can be increased when it is combined with Lopinavir.]
[N01BB09, ropivacaine, Lopinavir may decrease the excretion rate of Ropivacaine which could result in a higher serum level.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Lopinavir.]
[L01EX01, sunitinib, The serum concentration of Sunitinib can be increased when it is combined with Lopinavir.]
[A04AD12, aprepitant, The metabolism of Aprepitant can be decreased when combined with Lopinavir.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Lopinavir.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Lopinavir.]
[J05AE07, fosamprenavir, The serum concentration of Lopinavir can be decreased when it is combined with Fosamprenavir.]
[G04BE08, tadalafil, The serum concentration of Tadalafil can be increased when it is combined with Lopinavir.]
[S01BC05, ketorolac, The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Lopinavir.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be decreased when combined with Lopinavir.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Lopinavir.]
[N02BA06, salsalate, The risk or severity of nephrotoxicity can be increased when Salsalate is combined with Lopinavir.]
[R03AC12, salmeterol, The metabolism of Salmeterol can be decreased when combined with Lopinavir.]
[H05BA01, salmon calcitonin, Lopinavir may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.]
[C01CA07, dobutamine, Lopinavir may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Lopinavir.]
[C01CA04, dopamine, Lopinavir may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Dosulepin.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Lopinavir.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Lopinavir.]
[J01AA02, doxycycline, Lopinavir may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Lopinavir.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Lopinavir.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Lopinavir.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Droperidol.]
[A08AA10, sibutramine, The metabolism of Sibutramine can be decreased when combined with Lopinavir.]
[C10AA01, simvastatin, The serum concentration of Simvastatin can be increased when it is combined with Lopinavir.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CA02, sodium sulfate, Lopinavir may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[G03DB01, dydrogesterone, The metabolism of Dydrogesterone can be decreased when combined with Lopinavir.]
[R03DA01, dyphylline, Lopinavir may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Sultopride.]
[N02CC01, sumatriptan, The excretion of Sumatriptan can be decreased when combined with Lopinavir.]
[V04CX07, edrophonium, Lopinavir may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Lopinavir.]
[H01AA01, corticotropin, The serum concentration of Corticotropin can be increased when it is combined with Lopinavir.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Temafloxacin.]
[L01AX03, temozolomide, The serum concentration of Temozolomide can be increased when it is combined with Lopinavir.]
[M01AC02, tenoxicam, The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Lopinavir.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Lopinavir.]
[G04BD05, terodiline, The metabolism of Terodiline can be decreased when combined with Lopinavir.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Lopinavir.]
[C09AA02, enalapril, The excretion of Enalapril can be decreased when combined with Lopinavir.]
[M01AG02, tolfenamic acid, The metabolism of Tolfenamic acid can be decreased when combined with Lopinavir.]
[N06AG03, toloxatone, Lopinavir may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Lopinavir.]
[N03AX11, topiramate, Lopinavir may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L02BA02, toremifene, The metabolism of Toremifene can be decreased when combined with Lopinavir.]
[C03CA04, torsemide, The excretion of Torasemide can be decreased when combined with Lopinavir.]
[N05CC01, chloral hydrate, Lopinavir may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[H02CA01, trilostane, The serum concentration of Trilostane can be increased when it is combined with Lopinavir.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Triptorelin.]
[L01AA07, trofosfamide, The serum concentration of Trofosfamide can be increased when it is combined with Lopinavir.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Lopinavir.]
[L01CA04, vinorelbine, The serum concentration of Vinorelbine can be increased when it is combined with Lopinavir.]
[S01GX10, epinastine, The metabolism of Epinastine can be decreased when combined with Lopinavir.]
[N06AX16, venlafaxine, The metabolism of Venlafaxine can be decreased when combined with Lopinavir.]
[C08CA12, mepirodipine, The metabolism of Barnidipine can be decreased when combined with Lopinavir.]
[L01DB03, epirubicin, The serum concentration of Epirubicin can be increased when it is combined with Lopinavir.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Lopinavir.]
[M01AB04, zomepirac, The metabolism of Zomepirac can be decreased when combined with Lopinavir.]
[N03AX15, zonisamide, The metabolism of Zonisamide can be decreased when combined with Lopinavir.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Lopinavir.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Lopinavir.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Lopinavir.]
[L01XA02, carboplatin, The serum concentration of Carboplatin can be increased when it is combined with Lopinavir.]
[C02AC02, guanfacine, The metabolism of Guanfacine can be decreased when combined with Lopinavir.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Lopinavir.]
[G02AB03, ergonovine, The serum concentration of Ergometrine can be increased when it is combined with Lopinavir.]
[C04AE01, ergoloid mesylates, USP, The serum concentration of Ergoloid mesylate can be increased when it is combined with Lopinavir.]
[N02CA02, ergotamine, The serum concentration of Ergotamine can be increased when it is combined with Lopinavir.]
[L03AX05, pidotimod, Lopinavir may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, The metabolism of Estazolam can be decreased when combined with Lopinavir.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Lopinavir.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Lopinavir.]
[G03CA03, estradiol, The serum concentration of Estradiol can be decreased when it is combined with Lopinavir.]
[L01XX11, estramustine, The serum concentration of Estramustine can be increased when it is combined with Lopinavir.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be decreased when combined with Lopinavir.]
[J04AK02, ethambutol, Lopinavir may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The serum concentration of Fluticasone furoate can be increased when it is combined with Lopinavir.]
[R03BA05, fluticasone, The serum concentration of Fluticasone can be increased when it is combined with Lopinavir.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Lopinavir.]
[V08CA03, gadodiamide, Lopinavir may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[D07AC21, halobetasol, The serum concentration of Ulobetasol can be increased when it is combined with Lopinavir.]
[L02AA03, ethinyl estradiol, The serum concentration of Ethinylestradiol can be decreased when it is combined with Lopinavir.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Ibutilide.]
[N03AD01, ethosuximide, The metabolism of Ethosuximide can be decreased when combined with Lopinavir.]
[M01AC06, meloxicam, The metabolism of Meloxicam can be decreased when combined with Lopinavir.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Lopinavir.]
[N01AX07, etomidate, Lopinavir may decrease the excretion rate of Etomidate which could result in a higher serum level.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Lopinavir.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Lopinavir.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Lopinavir.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Lopinavir.]
[A02BA04, nizatidine, Nizatidine can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Lopinavir.]
[R06AX12, terfenadine, The metabolism of Lopinavir can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Lopinavir may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The serum concentration of Bupropion can be decreased when it is combined with Lopinavir.]
[N06AB08, fluvoxamine, The metabolism of Fluvoxamine can be decreased when combined with Lopinavir.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Lopinavir.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Leuprolide.]
[L04AA02, muromonab-CD3, The serum concentration of Muromonab can be increased when it is combined with Lopinavir.]
[M01CB01, gold sodium thiomalate, Lopinavir may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[A05AA01, chenodeoxycholic acid, The metabolism of Chenodeoxycholic acid can be decreased when combined with Lopinavir.]
[B05AA05, dextran, Lopinavir may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, The serum concentration of Dexrazoxane can be increased when it is combined with Lopinavir.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lopinavir.]
[A16AA01, levocarnitine, Lopinavir may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Lopinavir.]
[C08CA02, felodipine, The serum concentration of Felodipine can be increased when it is combined with Lopinavir.]
[C08EA01, fendiline, The metabolism of Fendiline can be decreased when combined with Lopinavir.]
[M01AE04, fenoprofen, The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Lopinavir.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Lopinavir.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Lopinavir.]
[L01BB06, clofarabine, The serum concentration of Clofarabine can be increased when it is combined with Lopinavir.]
[L04AA40, cladribine, The serum concentration of Cladribine can be increased when it is combined with Lopinavir.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Lopinavir.]
[G04BD02, flavoxate, Lopinavir may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Floctafenine.]
[J02AX01, flucytosine, The serum concentration of Flucytosine can be increased when it is combined with Lopinavir.]
[H02AA02, fludrocortisone, The serum concentration of Fludrocortisone can be increased when it is combined with Lopinavir.]
[V03AB25, flumazenil, Lopinavir may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The serum concentration of Flumethasone can be increased when it is combined with Lopinavir.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Lopinavir.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Lopinavir.]
[D07AC08, fluocinonide, The serum concentration of Fluocinonide can be increased when it is combined with Lopinavir.]
[H02AB03, fluocortolone, The serum concentration of Fluocortolone can be increased when it is combined with Lopinavir.]
[V03AZ01, ethanol, The metabolism of Ethanol can be decreased when combined with Lopinavir.]
[L01BC09, floxuridine, The serum concentration of Floxuridine can be increased when it is combined with Lopinavir.]
[S01CB05, fluorometholone, The serum concentration of Fluorometholone can be increased when it is combined with Lopinavir.]
[L01BC02, fluorouracil, The serum concentration of Fluorouracil can be increased when it is combined with Lopinavir.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Lopinavir.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Flupentixol.]
[D07AC07, flurandrenolide, The serum concentration of Flurandrenolide can be increased when it is combined with Lopinavir.]
[N05CD01, flurazepam, The metabolism of Flurazepam can be decreased when combined with Lopinavir.]
[S01BC04, flurbiprofen, The risk or severity of nephrotoxicity can be increased when Flurbiprofen is combined with Lopinavir.]
[N05AG01, fluspirilene, The metabolism of Fluspirilene can be decreased when combined with Lopinavir.]
[L02BB01, flutamide, The metabolism of Flutamide can be decreased when combined with Lopinavir.]
[V04CX02, folic acid, Lopinavir may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Lopinavir may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Lopinavir.]
[L01BC03, tegafur, Lopinavir may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[J05AE10, darunavir, The serum concentration of Darunavir can be decreased when it is combined with Lopinavir.]
[C03CA01, furosemide, The risk or severity of nephrotoxicity can be increased when Furosemide is combined with Lopinavir.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lopinavir is combined with Alendronic acid.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be increased when it is combined with Lopinavir.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Amisulpride.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Lopinavir.]
[C08DA02, gallopamil, The metabolism of Gallopamil can be decreased when combined with Lopinavir.]
[S01AD09, ganciclovir, Lopinavir may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[C10AB04, gemfibrozil, The metabolism of Gemfibrozil can be decreased when combined with Lopinavir.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Degarelix.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Lopinavir.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Lopinavir.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Lopinavir.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Methsuximide.]
[G03XA02, gestrinone, The serum concentration of Gestrinone can be decreased when it is combined with Lopinavir.]
[N01AH02, alfentanil, The metabolism of Alfentanil can be decreased when combined with Lopinavir.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Lopinavir.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Lopinavir.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Lopinavir.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Lopinavir.]
[N05CM18, dexmedetomidine, Lopinavir may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Lopinavir.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Lopinavir.]
[L01EX02, sorafenib, The serum concentration of Sorafenib can be increased when it is combined with Lopinavir.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Lopinavir.]
[M01CB04, aurothioglucose, Lopinavir may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Lopinavir may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Lopinavir.]
[C09AA09, fosinopril, Lopinavir may decrease the excretion rate of Fosinopril which could result in a higher serum level.]
[S01EX01, guanethidine, Lopinavir may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Goserelin.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Lopinavir.]
[D07AD02, halcinonide, The serum concentration of Halcinonide can be increased when it is combined with Lopinavir.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Haloperidol.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Lopinavir.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Histrelin.]
[N05AH04, quetiapine, The serum concentration of Quetiapine can be increased when it is combined with Lopinavir.]
[N06BX13, idebenone, Lopinavir may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Lopinavir.]
[L01CE02, irinotecan, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Lopinavir.]
[M04AA01, allopurinol, Lopinavir may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The metabolism of Losartan can be decreased when combined with Lopinavir.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Lopinavir.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Lopinavir.]
[C01CE02, milrinone, Lopinavir may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[L01XX03, altretamine, The serum concentration of Altretamine can be increased when it is combined with Lopinavir.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Lopinavir.]
[J05AG01, nevirapine, The serum concentration of Lopinavir can be decreased when it is combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Nilvadipine can be decreased when combined with Lopinavir.]
[M02AA26, nimesulide, The metabolism of Nimesulide can be decreased when combined with Lopinavir.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Oxatomide.]
[C09AA04, perindopril, Lopinavir may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, Lopinavir may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Lopinavir.]
[R05DA03, hydrocodone, The metabolism of Hydrocodone can be decreased when combined with Lopinavir.]
[S02BA01, hydrocortisone, The serum concentration of Hydrocortisone can be increased when it is combined with Lopinavir.]
[D07AC16, hydrocortisone aceponate, The serum concentration of Hydrocortisone aceponate can be increased when it is combined with Lopinavir.]
[D07AB11, hydrocortisone probutate, The serum concentration of Hydrocortisone probutate can be increased when it is combined with Lopinavir.]
[B05XA17, potassium acetate, Lopinavir may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[V03AB33, hydroxocobalamin, Lopinavir may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, The metabolism of Propiverine can be decreased when combined with Lopinavir.]
[P01BA02, hydroxychloroquine, The serum concentration of Hydroxychloroquine can be increased when it is combined with Lopinavir.]
[B05AA07, hetastarch, Lopinavir may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[G03DA03, 17-alpha-hydroxyprogesterone, The metabolism of Hydroxyprogesterone can be decreased when combined with Lopinavir.]
[L01XX05, hydroxyurea, The serum concentration of Hydroxyurea can be increased when it is combined with Lopinavir.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Hydroxyzine.]
[J04AB04, rifabutin, The serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Lopinavir.]
[S01BA13, rimexolone, The serum concentration of Rimexolone can be increased when it is combined with Lopinavir.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lopinavir is combined with Risedronic acid.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Lopinavir.]
[B05XA08, sodium acetate, Lopinavir may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The serum concentration of Idarubicin can be increased when it is combined with Lopinavir.]
[L01AA06, ifosfamide, The serum concentration of Ifosfamide can be increased when it is combined with Lopinavir.]
[N01AH03, sufentanil, The metabolism of Sufentanil can be decreased when combined with Lopinavir.]
[N06AA02, imipramine, The metabolism of Imipramine can be decreased when combined with Lopinavir.]
[L01CD01, paclitaxel, The serum concentration of Paclitaxel can be increased when it is combined with Lopinavir.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Terlipressin.]
[R01AD07, tixocortol, The serum concentration of Tixocortol can be increased when it is combined with Lopinavir.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Lopinavir.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Lopinavir.]
[C03BA11, indapamide, The metabolism of Indapamide can be decreased when combined with Lopinavir.]
[S01BC01, indomethacin, The serum concentration of Indomethacin can be increased when it is combined with Lopinavir.]
[A11HA07, inositol, Lopinavir may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The serum concentration of Interferon alfa-2a can be increased when it is combined with Lopinavir.]
[L03AB05, interferon alfa-2b, The serum concentration of Interferon alfa-2b can be increased when it is combined with Lopinavir.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be decreased when combined with Lopinavir.]
[S01XA28, varenicline, Lopinavir may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[L04AA25, eculizumab, The serum concentration of Eculizumab can be increased when it is combined with Lopinavir.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Lopinavir.]
[N05BA12, alprazolam, The serum concentration of Alprazolam can be increased when it is combined with Lopinavir.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Lopinavir.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Lopinavir.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lopinavir.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Lopinavir.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Anagrelide.]
[L03AB09, interferon alfacon-1, The serum concentration of Interferon alfacon-1 can be increased when it is combined with Lopinavir.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Lopinavir.]
[D06BB10, imiquimod, The serum concentration of Imiquimod can be increased when it is combined with Lopinavir.]
[P01AX06, atovaquone, The metabolism of Atovaquone can be decreased when combined with Lopinavir.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Lopinavir.]
[J04AC01, isoniazid, The metabolism of Lopinavir can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Lopinavir may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Lopinavir.]
[C01DA14, isosorbide mononitrate, Lopinavir may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, The metabolism of Isotretinoin can be decreased when combined with Lopinavir.]
[P02CF01, ivermectin, The metabolism of Ivermectin can be decreased when combined with Lopinavir.]
[N06AX18, reboxetine, The metabolism of Reboxetine can be decreased when combined with Lopinavir.]
[S01AA24, kanamycin, Lopinavir may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC07, tocilizumab, The serum concentration of Tocilizumab can be increased when it is combined with Lopinavir.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Lopinavir.]
[B01AC22, prasugrel, Lopinavir may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The serum concentration of Lopinavir can be increased when it is combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Levoketoconazole can be decreased when combined with Lopinavir.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Lopinavir.]
[M02AA10, ketoprofen, The risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Lopinavir.]
[L04AA24, abatacept, The serum concentration of Abatacept can be increased when it is combined with Lopinavir.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Mizolastine.]
[N04BC09, rotigotine, The metabolism of Rotigotine can be decreased when combined with Lopinavir.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of nephrotoxicity can be increased when Tiaprofenic acid is combined with Lopinavir.]
[C07AG01, labetalol, Lopinavir may decrease the excretion rate of Labetalol which could result in a higher serum level.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Lopinavir.]
[J05AX09, maraviroc, The metabolism of Maraviroc can be decreased when combined with Lopinavir.]
[A06AX03, lubiprostone, Lopinavir may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Lopinavir.]
[C03CC01, ethacrynic acid, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Lopinavir.]
[R05CB06, ambroxol, The metabolism of Ambroxol can be decreased when combined with Lopinavir.]
[L01DC03, mitomycin, The serum concentration of Mitomycin can be increased when it is combined with Lopinavir.]
[G03AD01, levonorgestrel, The serum concentration of Levonorgestrel can be decreased when it is combined with Lopinavir.]
[S02DA01, lidocaine, The metabolism of Lidocaine can be decreased when combined with Lopinavir.]
[C08EX01, lidoflazine, The metabolism of Lidoflazine can be decreased when combined with Lopinavir.]
[S01AA21, amikacin, Lopinavir may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Lopinavir.]
[N02CA07, lisuride, The serum concentration of Lisuride can be increased when it is combined with Lopinavir.]
[L01AD02, lomustine, The serum concentration of Lomustine can be increased when it is combined with Lopinavir.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Lopinavir.]
[N05BA06, lorazepam, The metabolism of Lorazepam can be decreased when combined with Lopinavir.]
[C10AA02, lovastatin, The serum concentration of Lovastatin can be increased when it is combined with Lopinavir.]
[G03DC03, lynestrenol, The serum concentration of Lynestrenol can be decreased when it is combined with Lopinavir.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be increased when it is combined with Lopinavir.]
[B05XA11, magnesium chloride, Lopinavir may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01BA05, pralatrexate, The serum concentration of Pralatrexate can be increased when it is combined with Lopinavir.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be decreased when combined with Lopinavir.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Lopinavir.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Lopinavir.]
[C02BB01, mecamylamine, Lopinavir may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[L01AA05, mechlorethamine, The serum concentration of Mechlorethamine can be increased when it is combined with Lopinavir.]
[M02AA18, meclofenamic acid, The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Lopinavir.]
[C01AA08, medigoxin, Lopinavir may decrease the excretion rate of Metildigoxin which could result in a higher serum level.]
[G03DB03, medrogestone, The metabolism of Medrogestone can be decreased when combined with Lopinavir.]
[P01BC02, mefloquine, The metabolism of Mefloquine can be decreased when combined with Lopinavir.]
[L01AA03, melphalan, The serum concentration of Melphalan can be increased when it is combined with Lopinavir.]
[N06DX01, memantine, Lopinavir may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The metabolism of Meperidine can be decreased when combined with Lopinavir.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Lopinavir.]
[N01BB03, mepivacaine, Lopinavir may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[G04BX16, tiopronin, Lopinavir may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Lopinavir may decrease the excretion rate of Mersalyl which could result in a higher serum level.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Mesoridazine.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be decreased when combined with Lopinavir.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Lopinavir.]
[A04AA04, dolasetron, The metabolism of Dolasetron can be decreased when combined with Lopinavir.]
[N07BC02, methadone, Methadone may increase the QTc-prolonging activities of Lopinavir.]
[N06BA03, methamphetamine, Lopinavir may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[A03AB07, methantheline, Methantheline can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05CM01, methaqualone, The metabolism of Methaqualone can be decreased when combined with Lopinavir.]
[G02CB05, metergoline, The serum concentration of Metergoline can be increased when it is combined with Lopinavir.]
[H03BB02, methimazole, The serum concentration of Methimazole can be increased when it is combined with Lopinavir.]
[L01BA04, pemetrexed, The serum concentration of Pemetrexed can be increased when it is combined with Lopinavir.]
[A11HA02, pyridoxine, Lopinavir may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[L04AX03, methotrexate, The serum concentration of Methotrexate can be increased when it is combined with Lopinavir.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Lopinavir.]
[D05BA02, methoxsalen, Lopinavir may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Lopinavir.]
[C02AB01, methyldopa, Lopinavir may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, The serum concentration of Methylene blue can be increased when it is combined with Lopinavir.]
[G02AB01, methylergonovine, The serum concentration of Methylergometrine can be increased when it is combined with Lopinavir.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Lopinavir.]
[H02AB04, methylprednisolone, The serum concentration of Methylprednisolone can be increased when it is combined with Lopinavir.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Lopinavir.]
[N02CA04, methysergide, The serum concentration of Methysergide can be increased when it is combined with Lopinavir.]
[A03FA01, metoclopramide, The metabolism of Metoclopramide can be decreased when combined with Lopinavir.]
[C03BA08, metolazone, Lopinavir may decrease the excretion rate of Metolazone which could result in a higher serum level.]
[C07AB02, metoprolol, Lopinavir may decrease the excretion rate of Metoprolol which could result in a higher serum level.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Lopinavir.]
[V04CD01, metyrapone, Lopinavir may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Lopinavir.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Lopinavir.]
[S02AA13, miconazole, The metabolism of Lopinavir can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Lopinavir.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Lopinavir.]
[G03XB01, mifepristone, The serum concentration of Mifepristone can be decreased when it is combined with Lopinavir.]
[J05AH01, zanamivir, Lopinavir may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The excretion of Valsartan can be decreased when combined with Lopinavir.]
[L01XX23, mitotane, The metabolism of Lopinavir can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The serum concentration of Mitoxantrone can be increased when it is combined with Lopinavir.]
[L03AC01, aldesleukin, The serum concentration of Aldesleukin can be increased when it is combined with Lopinavir.]
[C01BD01, amiodarone, The serum concentration of Amiodarone can be increased when it is combined with Lopinavir.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Lopinavir.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Lopinavir.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Lopinavir.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Latamoxef.]
[L04AB05, certolizumab pegol, The serum concentration of Certolizumab pegol can be increased when it is combined with Lopinavir.]
[G04BA01, ammonium chloride, Lopinavir may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA52, ofatumumab, The serum concentration of Ofatumumab can be increased when it is combined with Lopinavir.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Lopinavir.]
[L04AA06, mycophenolic acid, The serum concentration of Mycophenolic acid can be increased when it is combined with Lopinavir.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Lopinavir.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Lopinavir.]
[G03XC01, raloxifene, The excretion of Raloxifene can be decreased when combined with Lopinavir.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Lopinavir.]
[N03AB05, fosphenytoin, The serum concentration of Lopinavir can be decreased when it is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The serum concentration of Interferon beta-1b can be increased when it is combined with Lopinavir.]
[C07AA12, nadolol, Lopinavir may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01CA04, amoxicillin, Lopinavir may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, The metabolism of Lopinavir can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The serum concentration of Anakinra can be increased when it is combined with Lopinavir.]
[N06BA01, amphetamine, Lopinavir may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M02AA12, naproxen, The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Lopinavir.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Lopinavir.]
[N06AX21, duloxetine, Lopinavir may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N04BX01, tolcapone, Lopinavir may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[L01CD02, docetaxel, The serum concentration of Docetaxel can be increased when it is combined with Lopinavir.]
[L02BG04, letrozole, The metabolism of Letrozole can be decreased when combined with Lopinavir.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Neomycin.]
[A10BX02, repaglinide, The metabolism of Repaglinide can be decreased when combined with Lopinavir.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Levosimendan.]
[B01AC17, tirofiban, Lopinavir may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Lopinavir.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Lopinavir.]
[S01AA19, ampicillin, Lopinavir may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Lopinavir may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Lopinavir may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The metabolism of Desvenlafaxine can be decreased when combined with Lopinavir.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Lopinavir.]
[H05BX02, paricalcitol, The metabolism of Paricalcitol can be decreased when combined with Lopinavir.]
[C01CE01, inamrinone, Lopinavir may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[L01XX01, amsacrine, The serum concentration of Amsacrine can be increased when it is combined with Lopinavir.]
[C08CA04, nicardipine, The serum concentration of Nicardipine can be increased when it is combined with Lopinavir.]
[C04AE02, nicergoline, The serum concentration of Nicergoline can be increased when it is combined with Lopinavir.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Lopinavir.]
[C08CA05, nifedipine, The serum concentration of Nifedipine can be increased when it is combined with Lopinavir.]
[M02AA17, niflumic acid, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Niflumic acid.]
[C08CA06, nimodipine, The serum concentration of Nimodipine can be increased when it is combined with Lopinavir.]
[C08CA07, nisoldipine, The serum concentration of Nisoldipine can be increased when it is combined with Lopinavir.]
[N05CD02, nitrazepam, The metabolism of Nitrazepam can be decreased when combined with Lopinavir.]
[C08CA08, nitrendipine, The metabolism of Nitrendipine can be decreased when combined with Lopinavir.]
[R07AX01, nitric oxide, Lopinavir may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Lopinavir may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The metabolism of Zaleplon can be decreased when combined with Lopinavir.]
[N04BC05, pramipexole, Lopinavir may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Lopinavir may decrease the excretion rate of Nitroprusside which could result in a higher serum level.]
[G03DC02, norethindrone, The serum concentration of Norethisterone can be decreased when it is combined with Lopinavir.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Lopinavir.]
[G03AC07, norgestrienone, The serum concentration of Norgestrienone can be decreased when it is combined with Lopinavir.]
[C02KX01, bosentan, The serum concentration of Bosentan can be increased when it is combined with Lopinavir.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Lopinavir.]
[G02CA02, nylidrin, The metabolism of Nylidrin can be decreased when combined with Lopinavir.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lopinavir.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Ofloxacin.]
[L04AC04, rilonacept, The serum concentration of Rilonacept can be increased when it is combined with Lopinavir.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Lopinavir.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Lopinavir.]
[C01AC01, ouabain, The excretion of Ouabain can be decreased when combined with Lopinavir.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lopinavir is combined with Zoledronic acid.]
[J01CF04, oxacillin, Lopinavir may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[N05BA04, oxazepam, Lopinavir may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Oxolinic acid.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be decreased when combined with Lopinavir.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Lopinavir.]
[S01BC02, oxyphenbutazone, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Oxyphenbutazone.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lopinavir.]
[N05AH05, asenapine, The metabolism of Asenapine can be decreased when combined with Lopinavir.]
[J04AB30, capreomycin, Lopinavir may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G03DB06, chlormadinone, The serum concentration of Chlormadinone can be decreased when it is combined with Lopinavir.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Papaverine.]
[H02AB05, paramethasone, The serum concentration of Paramethasone can be increased when it is combined with Lopinavir.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Lopinavir.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Lopinavir.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Lopinavir.]
[C07AA23, penbutolol, Lopinavir may decrease the excretion rate of Penbutolol which could result in a higher serum level.]
[N05AG03, penfluridol, The metabolism of Penfluridol can be decreased when combined with Lopinavir.]
[M01CC01, penicillamine, The serum concentration of Penicillamine can be increased when it is combined with Lopinavir.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Lopinavir.]
[J01CE09, penicillin G procaine, Lopinavir may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, The metabolism of Lopinavir can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The serum concentration of Pentostatin can be increased when it is combined with Lopinavir.]
[C04AD03, pentoxifylline, Lopinavir may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[N04BC02, pergolide, The serum concentration of Pergolide can be increased when it is combined with Lopinavir.]
[C08EX02, perhexiline, The metabolism of Perhexiline can be decreased when combined with Lopinavir.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Lopinavir.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Phenazopyridine is combined with Lopinavir.]
[N06AF03, phenelzine, Lopinavir may decrease the excretion rate of Phenelzine which could result in a higher serum level.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Lopinavir.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Pheniramine.]
[N03AA02, phenobarbital, The serum concentration of Lopinavir can be decreased when it is combined with Phenobarbital.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Lopinavir.]
[A08AA01, phentermine, The metabolism of Phentermine can be decreased when combined with Lopinavir.]
[V03AB36, phentolamine, Lopinavir may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Lopinavir.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Lopinavir.]
[N03AB02, phenytoin, The serum concentration of Lopinavir can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The serum concentration of Golimumab can be increased when it is combined with Lopinavir.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Lopinavir.]
[B02BA01, vitamin K1, Lopinavir may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Lopinavir.]
[C08CX01, mibefradil, The metabolism of Mibefradil can be decreased when combined with Lopinavir.]
[N05AG02, pimozide, The serum concentration of Pimozide can be increased when it is combined with Lopinavir.]
[C07AA03, pindolol, Lopinavir may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Lopinavir.]
[J01CA12, piperacillin, Lopinavir may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The serum concentration of Saquinavir can be increased when it is combined with Lopinavir.]
[N05AC04, pipothiazine, The metabolism of Pipotiazine can be decreased when combined with Lopinavir.]
[N06BX03, piracetam, Lopinavir may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[S01BC06, piroxicam, The risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Lopinavir.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Lopinavir.]
[J01MA11, grepafloxacin, The metabolism of Grepafloxacin can be decreased when combined with Lopinavir.]
[J05AG02, delavirdine, The serum concentration of Lopinavir can be increased when it is combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Lopinavir.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Lopinavir.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Lopinavir.]
[L04AC08, canakinumab, The serum concentration of Canakinumab can be increased when it is combined with Lopinavir.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Lopinavir is combined with Polymyxin B.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be decreased when combined with Lopinavir.]
[B05XA01, potassium chloride, Lopinavir may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Lopinavir.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Prajmaline.]
[N05BA11, prazepam, The metabolism of Prazepam can be decreased when combined with Lopinavir.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Lopinavir.]
[S03BA02, prednisolone, The serum concentration of Prednisolone can be increased when it is combined with Lopinavir.]
[H02AB07, prednisone, The serum concentration of Prednisone can be increased when it is combined with Lopinavir.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Antazoline.]
[C01DX02, prenylamine, The metabolism of Prenylamine can be decreased when combined with Lopinavir.]
[P01BA03, primaquine, The metabolism of Primaquine can be decreased when combined with Lopinavir.]
[N03AA03, primidone, The metabolism of Lopinavir can be increased when combined with Primidone.]
[M04AB01, probenecid, Lopinavir may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Probucol.]
[C01BA02, procainamide, Lopinavir may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01XB01, procarbazine, The serum concentration of Procarbazine can be increased when it is combined with Lopinavir.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be decreased when combined with Lopinavir.]
[N05AB04, prochlorperazine, The metabolism of Prochlorperazine can be decreased when combined with Lopinavir.]
[G03DA04, progesterone, The serum concentration of Progesterone can be decreased when it is combined with Lopinavir.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Lopinavir.]
[G03DB07, promegestone, The metabolism of Promegestone can be decreased when combined with Lopinavir.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Lopinavir.]
[C01BC03, propafenone, The metabolism of Propafenone can be decreased when combined with Lopinavir.]
[A03AB05, propantheline, Lopinavir may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Lopinavir.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Lopinavir.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Lopinavir.]
[N02AC04, propoxyphene, The metabolism of Dextropropoxyphene can be decreased when combined with Lopinavir.]
[C07AA05, propranolol, The metabolism of Propranolol can be decreased when combined with Lopinavir.]
[H03BA02, propylthiouracil, The serum concentration of Propylthiouracil can be increased when it is combined with Lopinavir.]
[N02CC04, rizatriptan, Lopinavir may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, Lopinavir may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Lopinavir.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Lopinavir.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Lopinavir.]
[N07XX07, dalfampridine, Lopinavir may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Lopinavir may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Lopinavir may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Mepyramine.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Lopinavir.]
[C01BA01, quinidine, The serum concentration of Quinidine can be increased when it is combined with Lopinavir.]
[P01BC01, quinine, The serum concentration of Quinine can be increased when it is combined with Lopinavir.]
[D07AC10, diflorasone, The serum concentration of Diflorasone can be increased when it is combined with Lopinavir.]
[C02AA02, reserpine, Lopinavir may decrease the excretion rate of Reserpine which could result in a higher serum level.]
[J05AP01, ribavirin, Lopinavir may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J04AB02, rifampin, The serum concentration of Lopinavir can be decreased when it is combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Roxithromycin can be decreased when combined with Lopinavir.]
[N02BA05, salicylamide, The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Salicylamide.]
[A07EC01, sulfasalazine, The serum concentration of Sulfasalazine can be increased when it is combined with Lopinavir.]
[S01BC08, salicylic acid, The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Lopinavir.]
[S01FA02, scopolamine, The metabolism of Scopolamine can be decreased when combined with Lopinavir.]
[N05CA06, secobarbital, Lopinavir may decrease the excretion rate of Secobarbital which could result in a higher serum level.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Lopinavir.]
[L01FA03, obinutuzumab, The serum concentration of Obinutuzumab can be increased when it is combined with Lopinavir.]
[V04CC03, sincalide, The excretion of Sincalide can be decreased when combined with Lopinavir.]
[J01GB08, sisomicin, Lopinavir may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Lopinavir may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[M05BX04, denosumab, The serum concentration of Denosumab can be increased when it is combined with Lopinavir.]
[V04CC01, sorbitol, Lopinavir may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Sotalol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Lopinavir.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Lopinavir.]
[V09AB03, ioflupane I-123, Lopinavir may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Lopinavir.]
[V09AA01, technetium Tc 99m exametazime, Lopinavir may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Lopinavir may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[N03AG01, valproic acid, The serum concentration of Valproic acid can be decreased when it is combined with Lopinavir.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lopinavir is combined with Etidronic acid.]
[D07AB02, hydrocortisone butyrate, The serum concentration of Hydrocortisone butyrate can be increased when it is combined with Lopinavir.]
[D10AX03, azelaic acid, Lopinavir may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[S02DA03, antipyrine, The serum concentration of Antipyrine can be increased when it is combined with Ritonavir.]
[G03XB02, ulipristal, The serum concentration of Ulipristal can be decreased when it is combined with Ritonavir.]
[J01EC02, sulfadiazine, The serum concentration of Sulfadiazine can be increased when it is combined with Ritonavir.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Ritonavir.]
[M04AB02, sulfinpyrazone, The serum concentration of Sulfinpyrazone can be increased when it is combined with Ritonavir.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Ritonavir.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Sulpiride.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Ritonavir.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Ritonavir.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Ritonavir.]
[L02BA01, tamoxifen, The serum concentration of Tamoxifen can be increased when it is combined with Ritonavir.]
[L01CB02, teniposide, The serum concentration of Teniposide can be increased when it is combined with Ritonavir.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Ritonavir.]
[G03BA03, testosterone, The serum concentration of Testosterone can be increased when it is combined with Ritonavir.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Ritonavir.]
[S03AA02, tetracycline, The serum concentration of Tetracycline can be increased when it is combined with Ritonavir.]
[N05AE05, lurasidone, The serum concentration of Lurasidone can be increased when it is combined with Ritonavir.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Ritonavir.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Ritonavir.]
[L04AX02, thalidomide, The metabolism of Ritonavir can be increased when combined with Thalidomide.]
[R03DA07, theobromine, The metabolism of Theobromine can be increased when combined with Ritonavir.]
[R03DA04, theophylline, The serum concentration of Theophylline can be decreased when it is combined with Ritonavir.]
[P02CA02, thiabendazole, The metabolism of Thiabendazole can be increased when combined with Ritonavir.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Eribulin.]
[L01AC01, thiotepa, The serum concentration of Thiotepa can be increased when it is combined with Ritonavir.]
[N05CA19, thiopental, The metabolism of Thiopental can be decreased when combined with Ritonavir.]
[N05AC02, thioridazine, The metabolism of Thioridazine can be decreased when combined with Ritonavir.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Ritonavir.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Ritonavir.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Ritonavir.]
[P01AB02, tinidazole, The serum concentration of Tinidazole can be increased when it is combined with Ritonavir.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Ritonavir.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Ritonavir.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Ritonavir.]
[N06AF04, tranylcypromine, The metabolism of Ritonavir can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The serum concentration of Trazodone can be increased when it is combined with Ritonavir.]
[L01XF01, tretinoin, The serum concentration of Tretinoin can be increased when it is combined with Ritonavir.]
[S01BA05, triamcinolone, The serum concentration of Triamcinolone can be increased when it is combined with Ritonavir.]
[C03DB02, triamterene, The metabolism of Triamterene can be increased when combined with Ritonavir.]
[N05CD05, triazolam, The serum concentration of Triazolam can be increased when it is combined with Ritonavir.]
[N05AB06, trifluoperazine, The metabolism of Trifluoperazine can be increased when combined with Ritonavir.]
[S01BA09, clobetasone, The serum concentration of Clobetasone can be increased when it is combined with Ritonavir.]
[S01BA10, alclometasone, The serum concentration of Alclometasone can be increased when it is combined with Ritonavir.]
[R03BA07, mometasone, The serum concentration of Mometasone can be increased when it is combined with Ritonavir.]
[A03AA05, trimebutine, The serum concentration of Trimebutine can be increased when it is combined with Ritonavir.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Alimemazine.]
[N03AC02, trimethadione, The serum concentration of Trimethadione can be increased when it is combined with Ritonavir.]
[J01EA01, trimethoprim, The serum concentration of Trimethoprim can be increased when it is combined with Ritonavir.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Ritonavir.]
[R06AC04, tripelennamine, The metabolism of Ritonavir can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Ritonavir.]
[J01FA08, troleandomycin, The serum concentration of Troleandomycin can be increased when it is combined with Ritonavir.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Ritonavir.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Ritonavir.]
[L01EX04, vandetanib, The serum concentration of Vandetanib can be increased when it is combined with Ritonavir.]
[L02BX03, abiraterone, The serum concentration of Abiraterone can be increased when it is combined with Ritonavir.]
[A10BH05, linagliptin, The serum concentration of Linagliptin can be increased when it is combined with Ritonavir.]
[J05AP03, boceprevir, The serum concentration of Boceprevir can be decreased when it is combined with Ritonavir.]
[J05AP02, telaprevir, The serum concentration of Telaprevir can be decreased when it is combined with Ritonavir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be increased when it is combined with Ritonavir.]
[N03AX21, ezogabine, The metabolism of Ezogabine can be increased when combined with Ritonavir.]
[B01AF01, rivaroxaban, The serum concentration of Rivaroxaban can be increased when it is combined with Ritonavir.]
[R03AC18, indacaterol, The serum concentration of Indacaterol can be increased when it is combined with Ritonavir.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Ritonavir.]
[C08DA01, verapamil, The serum concentration of Verapamil can be increased when it is combined with Ritonavir.]
[N06AX09, viloxazine, The metabolism of Ritonavir can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Ritonavir.]
[L01CA02, vincristine, The serum concentration of Vincristine can be increased when it is combined with Ritonavir.]
[L01CA03, vindesine, The serum concentration of Vindesine can be increased when it is combined with Ritonavir.]
[A11HA03, vitamin E, The serum concentration of Vitamin E can be increased when it is combined with Ritonavir.]
[B01AA03, warfarin, The serum concentration of Warfarin can be decreased when it is combined with Ritonavir.]
[S01AA13, fusidic acid, The serum concentration of Fusidic acid can be increased when it is combined with Ritonavir.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Pipemidic acid.]
[J05AF01, zidovudine, The serum concentration of Zidovudine can be increased when it is combined with Ritonavir.]
[N05AF05, zuclopenthixol, The serum concentration of Zuclopenthixol can be increased when it is combined with Ritonavir.]
[J05AE02, indinavir, The serum concentration of Indinavir can be increased when it is combined with Ritonavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ritonavir.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ritonavir.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Ritonavir.]
[L01ED01, crizotinib, The serum concentration of Crizotinib can be increased when it is combined with Ritonavir.]
[R03DC01, zafirlukast, The metabolism of Zafirlukast can be increased when combined with Ritonavir.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Ziprasidone.]
[G03AC10, drospirenone, The serum concentration of Drospirenone can be decreased when it is combined with Ritonavir.]
[N02BA01, aspirin, The metabolism of Acetylsalicylic acid can be increased when combined with Ritonavir.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Ritonavir.]
[G04BD07, tolterodine, The serum concentration of Tolterodine can be increased when it is combined with Ritonavir.]
[C07AB03, atenolol, The metabolism of Atenolol can be decreased when combined with Ritonavir.]
[J02AC03, voriconazole, The serum concentration of Voriconazole can be decreased when it is combined with Ritonavir.]
[S01FA01, atropine, Ritonavir may decrease the excretion rate of Atropine which could result in a higher serum level.]
[L01XJ01, vismodegib, The serum concentration of Vismodegib can be increased when it is combined with Ritonavir.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Ritonavir.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Ritonavir.]
[H02AB11, prednylidene, The serum concentration of Prednylidene can be increased when it is combined with Ritonavir.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be increased when combined with Ritonavir.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Ritonavir.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Ritonavir.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Ritonavir.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Ritonavir.]
[A08AA11, lorcaserin, The serum concentration of Lorcaserin can be increased when it is combined with Ritonavir.]
[G04BD12, mirabegron, The serum concentration of Ritonavir can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be increased when it is combined with Ritonavir.]
[V03AX03, cobicistat, The serum concentration of Cobicistat can be increased when it is combined with Ritonavir.]
[J05AJ02, elvitegravir, The serum concentration of Elvitegravir can be increased when it is combined with Ritonavir.]
[L02BB04, enzalutamide, The serum concentration of Enzalutamide can be increased when it is combined with Ritonavir.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Ritonavir.]
[L04AA31, teriflunomide, Ritonavir may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AA01, aldosterone, The serum concentration of Aldosterone can be increased when it is combined with Ritonavir.]
[L01EX05, regorafenib, The serum concentration of Regorafenib can be increased when it is combined with Ritonavir.]
[N05CA04, barbital, The metabolism of Barbital can be decreased when combined with Ritonavir.]
[J05AE04, nelfinavir, The serum concentration of Nelfinavir can be increased when it is combined with Ritonavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Ritonavir.]
[N04BD02, rasagiline, The metabolism of Rasagiline can be increased when combined with Ritonavir.]
[C08CA13, lercanidipine, The serum concentration of Lercanidipine can be increased when it is combined with Ritonavir.]
[N06DA02, donepezil, The serum concentration of Donepezil can be increased when it is combined with Ritonavir.]
[N03AX22, perampanel, The serum concentration of Perampanel can be increased when it is combined with Ritonavir.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Ritonavir.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be increased when combined with Ritonavir.]
[G04BD10, darifenacin, The serum concentration of Darifenacin can be increased when it is combined with Ritonavir.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Ritonavir.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Pasireotide.]
[G04BE03, sildenafil, The serum concentration of Sildenafil can be increased when it is combined with Ritonavir.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Ritonavir.]
[B01AF02, apixaban, The serum concentration of Apixaban can be increased when it is combined with Ritonavir.]
[C10AX12, lomitapide, The serum concentration of Lomitapide can be increased when it is combined with Ritonavir.]
[J04AK05, bedaquiline, The metabolism of Bedaquiline can be decreased when combined with Ritonavir.]
[C04AX11, bencyclane, The serum concentration of Bencyclane can be increased when it is combined with Ritonavir.]
[A10BH04, alogliptin, The serum concentration of Alogliptin can be increased when it is combined with Ritonavir.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Ritonavir can be decreased when combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Ritonavir.]
[G03XC05, ospemifene, The serum concentration of Ospemifene can be increased when it is combined with Ritonavir.]
[A10BK02, canagliflozin, The metabolism of Canagliflozin can be increased when combined with Ritonavir.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Gemifloxacin.]
[M04AB03, benzbromarone, Ritonavir may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Tegaserod can be decreased when combined with Ritonavir.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Ritonavir.]
[J05AX07, enfuvirtide, The serum concentration of Enfuvirtide can be increased when it is combined with Ritonavir.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Ritonavir.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Ritonavir.]
[J02AX04, caspofungin, The excretion of Caspofungin can be decreased when combined with Ritonavir.]
[M01AH01, celecoxib, The serum concentration of Celecoxib can be increased when it is combined with Ritonavir.]
[L04AA18, everolimus, The serum concentration of Everolimus can be increased when it is combined with Ritonavir.]
[N04AC01, benztropine, The metabolism of Benzatropine can be decreased when combined with Ritonavir.]
[L01EC02, dabrafenib, The serum concentration of Dabrafenib can be increased when it is combined with Ritonavir.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Ritonavir.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Ritonavir.]
[N06AX28, levomilnacipran, The serum concentration of Levomilnacipran can be increased when it is combined with Ritonavir.]
[J05AJ03, dolutegravir, The metabolism of Dolutegravir can be increased when combined with Ritonavir.]
[C08EA02, bepridil, The serum concentration of Bepridil can be increased when it is combined with Ritonavir.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Ritonavir.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Ritonavir.]
[A05AA03, cholic acid, Cholic Acid may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[G03XC02, bazedoxifene, The metabolism of Bazedoxifene can be increased when combined with Ritonavir.]
[C02KX04, macitentan, The serum concentration of Macitentan can be increased when it is combined with Ritonavir.]
[L01EL01, ibrutinib, The serum concentration of Ibrutinib can be increased when it is combined with Ritonavir.]
[N06AX26, vortioxetine, The serum concentration of Vortioxetine can be increased when it is combined with Ritonavir.]
[G03AC08, etonogestrel, The serum concentration of Etonogestrel can be decreased when it is combined with Ritonavir.]
[N03AF04, eslicarbazepine, The metabolism of Eslicarbazepine can be increased when combined with Ritonavir.]
[J05AP05, simeprevir, The serum concentration of Simeprevir can be increased when it is combined with Ritonavir.]
[J05AP08, sofosbuvir, Ritonavir may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, The serum concentration of Dapagliflozin can be increased when it is combined with Ritonavir.]
[C07AB04, acebutolol, The metabolism of Acebutolol can be decreased when combined with Ritonavir.]
[N05CH03, tasimelteon, The serum concentration of Tasimelteon can be increased when it is combined with Ritonavir.]
[A16AA07, metreleptin, The metabolism of Ritonavir can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The serum concentration of Apremilast can be increased when it is combined with Ritonavir.]
[S03BA03, betamethasone, The serum concentration of Betamethasone can be increased when it is combined with Ritonavir.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Ritonavir.]
[C10AB02, bezafibrate, The serum concentration of Bezafibrate can be increased when it is combined with Ritonavir.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Ritonavir.]
[L04AC11, siltuximab, The metabolism of Ritonavir can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Ritonavir.]
[B01AC26, vorapaxar, The serum concentration of Vorapaxar can be increased when it is combined with Ritonavir.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ritonavir.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be decreased when it is combined with Ritonavir.]
[L01XH04, belinostat, The metabolism of Belinostat can be increased when combined with Ritonavir.]
[L01EM01, idelalisib, The serum concentration of Idelalisib can be increased when it is combined with Ritonavir.]
[N07XX08, tafamidis, The serum concentration of Ritonavir can be increased when it is combined with Tafamidis.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ritonavir.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Ritonavir.]
[N05CM19, suvorexant, The serum concentration of Suvorexant can be increased when it is combined with Ritonavir.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Ritonavir.]
[J01XA05, oritavancin, The metabolism of Ritonavir can be decreased when combined with Oritavancin.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ritonavir.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Ritonavir.]
[N04AA02, biperiden, The metabolism of Ritonavir can be decreased when combined with Biperiden.]
[A11HA08, tocophersolan, The serum concentration of Tocofersolan can be increased when it is combined with Ritonavir.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Ritonavir.]
[L01EX09, nintedanib, The serum concentration of Nintedanib can be increased when it is combined with Ritonavir.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Ritonavir.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be increased when combined with Ritonavir.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Ritonavir.]
[N06AX11, mirtazapine, The serum concentration of Mirtazapine can be increased when it is combined with Ritonavir.]
[L04AC10, secukinumab, The metabolism of Ritonavir can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Ritonavir.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Ritonavir.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Ritonavir.]
[N02BE01, acetaminophen, The serum concentration of Acetaminophen can be increased when it is combined with Ritonavir.]
[C01EB17, ivabradine, The serum concentration of Ivabradine can be increased when it is combined with Ritonavir.]
[J05AP06, asunaprevir, The serum concentration of Asunaprevir can be increased when it is combined with Ritonavir.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Ritonavir.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Ritonavir.]
[L01XJ02, sonidegib, The serum concentration of Sonidegib can be increased when it is combined with Ritonavir.]
[A04AD14, rolapitant, The serum concentration of Rolapitant can be increased when it is combined with Ritonavir.]
[G02CX02, flibanserin, The metabolism of Flibanserin can be decreased when combined with Ritonavir.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AX15, cariprazine, The metabolism of Cariprazine can be decreased when combined with Ritonavir.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Ritonavir.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Ritonavir.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Acipimox.]
[A02BC03, lansoprazole, The serum concentration of Lansoprazole can be increased when it is combined with Ritonavir.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Ritonavir.]
[J02AC05, isavuconazole, The serum concentration of Isavuconazole can be increased when it is combined with Ritonavir.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Ritonavir.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ritonavir.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Ritonavir.]
[L01XG03, ixazomib, The serum concentration of Ixazomib can be increased when it is combined with Ritonavir.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Ritonavir.]
[B01AC27, selexipag, The serum concentration of Selexipag can be increased when it is combined with Ritonavir.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ritonavir.]
[G04CA01, alfuzosin, The serum concentration of Alfuzosin can be increased when it is combined with Ritonavir.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be increased when combined with Ritonavir.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Ritonavir.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Ritonavir.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AX23, brivaracetam, The serum concentration of Brivaracetam can be increased when it is combined with Ritonavir.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Ritonavir.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be increased when combined with Ritonavir.]
[N04BC01, bromocriptine, The serum concentration of Bromocriptine can be increased when it is combined with Ritonavir.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[D07AC11, amcinonide, The serum concentration of Amcinonide can be increased when it is combined with Ritonavir.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ritonavir.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be decreased when combined with Ritonavir.]
[N05AX17, pimavanserin, The serum concentration of Pimavanserin can be increased when it is combined with Ritonavir.]
[C03CA02, bumetanide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Bumetanide.]
[N01BB01, bupivacaine, The serum concentration of Bupivacaine can be increased when it is combined with Ritonavir.]
[C07AA19, bupranolol, The metabolism of Bupranolol can be decreased when combined with Ritonavir.]
[N07BC01, buprenorphine, The serum concentration of Buprenorphine can be increased when it is combined with Ritonavir.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Buserelin.]
[N05BE01, buspirone, The serum concentration of Buspirone can be increased when it is combined with Ritonavir.]
[L01AB01, busulfan, The serum concentration of Busulfan can be increased when it is combined with Ritonavir.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Arsenic trioxide.]
[P01BE02, artemether, The serum concentration of Artemether can be increased when it is combined with Ritonavir.]
[P01BE03, artesunate, The serum concentration of Artesunate can be decreased when it is combined with Ritonavir.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Azatadine.]
[S01GX07, azelastine, The serum concentration of Azelastine can be increased when it is combined with Ritonavir.]
[L01XK03, rucaparib, The serum concentration of Rucaparib can be increased when it is combined with Ritonavir.]
[S01AA26, azithromycin, The serum concentration of Azithromycin can be increased when it is combined with Ritonavir.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be decreased when combined with Ritonavir.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be increased when combined with Ritonavir.]
[N07XX16, deutetrabenazine, The serum concentration of Deutetrabenazine can be increased when it is combined with Ritonavir.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ritonavir.]
[N06BC01, caffeine, Caffeine may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Ritonavir.]
[D05AX03, calcitriol, The serum concentration of Calcitriol can be increased when it is combined with Ritonavir.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AF06, abacavir, The serum concentration of Abacavir can be decreased when it is combined with Ritonavir.]
[J05AE09, tipranavir, The serum concentration of Tipranavir can be increased when it is combined with Ritonavir.]
[N07XX13, valbenazine, The serum concentration of Valbenazine can be increased when it is combined with Ritonavir.]
[L04AB02, infliximab, The metabolism of Ritonavir can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The serum concentration of Midostaurin can be increased when it is combined with Ritonavir.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Ritonavir.]
[N04BD03, safinamide, The serum concentration of Safinamide can be increased when it is combined with Ritonavir.]
[J01MA23, delafloxacin, The metabolism of Delafloxacin can be increased when combined with Ritonavir.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Ritonavir.]
[P03AC02, bioallethrin, The serum concentration of Bioallethrin can be increased when it is combined with Ritonavir.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be increased when combined with Ritonavir.]
[L01XX59, enasidenib, The serum concentration of Enasidenib can be increased when it is combined with Ritonavir.]
[L01EH02, neratinib, The serum concentration of Neratinib can be increased when it is combined with Ritonavir.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ritonavir.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Ritonavir.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Ritonavir.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Ritonavir.]
[S01EC04, brinzolamide, The serum concentration of Brinzolamide can be increased when it is combined with Ritonavir.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Ritonavir.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Ritonavir.]
[N05CD09, brotizolam, The serum concentration of Brotizolam can be increased when it is combined with Ritonavir.]
[R03BA02, budesonide, The serum concentration of Budesonide can be increased when it is combined with Ritonavir.]
[L01EL02, acalabrutinib, The serum concentration of Acalabrutinib can be increased when it is combined with Ritonavir.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Ritonavir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The bioavailability of Acetyldigoxin can be increased when combined with Ritonavir.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Ritonavir.]
[N01BX04, capsaicin, The metabolism of Capsaicin can be increased when combined with Ritonavir.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Ritonavir.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Acrivastine.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Captopril.]
[V04CD06, macimorelin, The serum concentration of Macimorelin can be increased when it is combined with Ritonavir.]
[L02BB05, apalutamide, The serum concentration of Ritonavir can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Ritonavir can be decreased when it is combined with Carbamazepine.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Ritonavir.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Carbinoxamine.]
[C07AG02, carvedilol, The serum concentration of Carvedilol can be increased when it is combined with Ritonavir.]
[B02BX09, fostamatinib, The serum concentration of R406, an active metabolite of Fostamatinib, can be increased when used in combination with Ritonavir.]
[N03AX24, cannabidiol, The serum concentration of Cannabidiol can be increased when it is combined with Ritonavir.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[L04AA37, baricitinib, The serum concentration of Baricitinib can be increased when it is combined with Ritonavir.]
[V03AE10, sodium zirconium cyclosilicate, Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EC03, encorafenib, The serum concentration of Encorafenib can be increased when it is combined with Ritonavir.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Ritonavir.]
[C07AB08, celiprolol, The metabolism of Celiprolol can be decreased when combined with Ritonavir.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Ritonavir.]
[L01XX62, ivosidenib, The serum concentration of Ivosidenib can be increased when it is combined with Ritonavir.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Ritonavir.]
[A16AX14, migalastat, The metabolism of Migalastat can be increased when combined with Ritonavir.]
[N03AX17, stiripentol, The serum concentration of Stiripentol can be increased when it is combined with Ritonavir.]
[B02BX07, lusutrombopag, Ritonavir may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.]
[J05AG06, doravirine, The serum concentration of Doravirine can be increased when it is combined with Ritonavir.]
[J01AA13, eravacycline, The serum concentration of Eravacycline can be increased when it is combined with Ritonavir.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Ritonavir.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Ritonavir.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Ritonavir.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ritonavir.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Ritonavir.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be increased when combined with Ritonavir.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be increased when combined with Ritonavir.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Inotersen.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Ritonavir.]
[M03BA02, carisoprodol, The metabolism of Carisoprodol can be decreased when combined with Ritonavir.]
[R03BB08, revefenacin, Ritonavir may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01ED05, lorlatinib, The serum concentration of Lorlatinib can be increased when it is combined with Ritonavir.]
[L04AA39, emapalumab, The metabolism of Ritonavir can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Carmustine can be increased when combined with Ritonavir.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Ritonavir.]
[L01EX13, gilteritinib, The serum concentration of Gilteritinib can be increased when it is combined with Ritonavir.]
[L01XJ03, glasdegib, The serum concentration of Glasdegib can be increased when it is combined with Ritonavir.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Amifampridine.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Ritonavir.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Cibenzoline.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Ritonavir.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Ciprofibrate.]
[P02BX04, triclabendazole, The serum concentration of Triclabendazole can be increased when it is combined with Ritonavir.]
[N06AX27, esketamine, The serum concentration of Esketamine can be increased when it is combined with Ritonavir.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Ritonavir is combined with Siponimod.]
[J01FA09, clarithromycin, The serum concentration of Clarithromycin can be increased when it is combined with Ritonavir.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Ritonavir.]
[N05BA09, clobazam, The serum concentration of Clobazam can be increased when it is combined with Ritonavir.]
[H02AB14, cloprednol, The metabolism of Cloprednol can be decreased when combined with Ritonavir.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Ubidecarenone.]
[C09CA06, candesartan, The metabolism of Candesartan can be increased when combined with Ritonavir.]
[L04AB01, etanercept, The metabolism of Ritonavir can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Cortivazol can be decreased when combined with Ritonavir.]
[L01EM03, alpelisib, The serum concentration of Alpelisib can be increased when it is combined with Ritonavir.]
[L01FX14, polatuzumab vedotin, The risk or severity of adverse effects can be increased when Ritonavir is combined with Polatuzumab vedotin.]
[J01DC04, cefaclor, Ritonavir may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[L01XX66, selinexor, The serum concentration of Selinexor can be increased when it is combined with Ritonavir.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Ritonavir.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Ritonavir.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Cicletanine.]
[M03BX08, cyclobenzaprine, The serum concentration of Cyclobenzaprine can be increased when it is combined with Ritonavir.]
[L04AA44, upadacitinib, The serum concentration of Upadacitinib can be increased when it is combined with Ritonavir.]
[L01EJ02, fedratinib, The serum concentration of Fedratinib can be increased when it is combined with Ritonavir.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Ritonavir.]
[N07XX11, pitolisant, The serum concentration of Ritonavir can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The serum concentration of Pretomanid can be increased when it is combined with Ritonavir.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Ritonavir.]
[N04CX01, istradefylline, The serum concentration of Istradefylline can be increased when it is combined with Ritonavir.]
[G04BE04, yohimbine, The serum concentration of Yohimbine can be increased when it is combined with Ritonavir.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ritonavir.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Ritonavir.]
[J01DB01, cephalexin, The serum concentration of Cephalexin can be increased when it is combined with Ritonavir.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be increased when it is combined with Ritonavir.]
[G03DB05, demegestone, The serum concentration of Demegestone can be decreased when it is combined with Ritonavir.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Ritonavir.]
[N02CC08, lasmiditan, The serum concentration of Ritonavir can be increased when it is combined with Lasmiditan.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Ritonavir.]
[G03AC09, desogestrel, The serum concentration of Desogestrel can be decreased when it is combined with Ritonavir.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Ritonavir.]
[N03AX25, cenobamate, The serum concentration of Ritonavir can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Ritonavir can be increased when it is combined with Givosiran.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Ritonavir.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ritonavir.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ritonavir.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Ritonavir.]
[L01EX18, avapritinib, The serum concentration of Avapritinib can be increased when it is combined with Ritonavir.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Ritonavir.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Ritonavir.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be increased when it is combined with Ritonavir.]
[M01AX21, diacetylrhein, The metabolism of Ritonavir can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be decreased when combined with Ritonavir.]
[C10AX15, bempedoic acid, The excretion of Bempedoic acid can be decreased when combined with Ritonavir.]
[J05AB16, remdesivir, The serum concentration of Remdesivir can be increased when it is combined with Ritonavir.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Gatifloxacin.]
[H02CA02, osilodrostat, The serum concentration of Osilodrostat can be increased when it is combined with Ritonavir.]
[J05AE05, amprenavir, The serum concentration of Amprenavir can be increased when it is combined with Ritonavir.]
[N02CC07, frovatriptan, The metabolism of Frovatriptan can be increased when combined with Ritonavir.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be decreased when combined with Ritonavir.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Ritonavir.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Ritonavir.]
[G03DB08, dienogest, The serum concentration of Dienogest can be decreased when it is combined with Ritonavir.]
[D07AC19, difluprednate, The serum concentration of Difluprednate can be increased when it is combined with Ritonavir.]
[N02AA08, dihydrocodeine, The serum concentration of Dihydrocodeine can be increased when it is combined with Ritonavir.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Ritonavir.]
[M01AH02, rofecoxib, The serum concentration of Rofecoxib can be increased when it is combined with Ritonavir.]
[L01XF03, bexarotene, The serum concentration of Bexarotene can be increased when it is combined with Ritonavir.]
[C08CA16, clevidipine, The serum concentration of Clevidipine can be increased when it is combined with Ritonavir.]
[C01BD07, dronedarone, The serum concentration of Dronedarone can be increased when it is combined with Ritonavir.]
[S03AA08, chloramphenicol, The metabolism of Ritonavir can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Chlorcyclizine.]
[L01EN02, pemigatinib, The serum concentration of Pemigatinib can be increased when it is combined with Ritonavir.]
[L01FX17, sacituzumab govitecan, The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Ritonavir.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Ritonavir.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be increased when it is combined with Ritonavir.]
[D07XB03, fluprednidene, The serum concentration of Fluprednidene can be increased when it is combined with Ritonavir.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be increased when combined with Ritonavir.]
[G04BD09, trospium, The metabolism of Ritonavir can be decreased when combined with Trospium.]
[L01EX19, ripretinib, The serum concentration of Ripretinib can be increased when it is combined with Ritonavir.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be increased when it is combined with Ritonavir.]
[N05CM02, chlormethiazole, The serum concentration of Clomethiazole can be increased when it is combined with Ritonavir.]
[L01XX69, lurbinectedin, The serum concentration of Lurbinectedin can be increased when it is combined with Ritonavir.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Ritonavir.]
[R06AX22, ebastine, The serum concentration of Ebastine can be increased when it is combined with Ritonavir.]
[P01BB01, proguanil, The serum concentration of Proguanil can be decreased when it is combined with Ritonavir.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Ritonavir.]
[L04AC19, satralizumab, The serum concentration of Ritonavir can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be increased when it is combined with Ritonavir.]
[P01BA01, chloroquine, The serum concentration of Chloroquine can be increased when it is combined with Ritonavir.]
[L01EX23, pralsetinib, The serum concentration of Pralsetinib can be increased when it is combined with Ritonavir.]
[G03CA06, chlorotrianisene, The risk or severity of liver enzyme elevations can be increased when Chlorotrianisene is combined with Ritonavir.]
[R06AB04, chlorpheniramine, The serum concentration of Chlorpheniramine can be increased when it is combined with Ritonavir.]
[N05AA01, chlorpromazine, The serum concentration of Chlorpromazine can be increased when it is combined with Ritonavir.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ritonavir.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Chlorprothixene.]
[M03BB03, chlorzoxazone, The serum concentration of Chlorzoxazone can be increased when it is combined with Ritonavir.]
[A11CC05, cholecalciferol, The serum concentration of Cholecalciferol can be increased when it is combined with Ritonavir.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Ritonavir.]
[N06BX18, vinpocetine, The serum concentration of Vinpocetine can be increased when it is combined with Ritonavir.]
[G03DC06, ethynodiol, The serum concentration of Etynodiol can be decreased when it is combined with Ritonavir.]
[M01AB08, etodolac, The metabolism of Etodolac can be increased when combined with Ritonavir.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Etofibrate.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Ritonavir.]
[A16AX20, lonafarnib, The serum concentration of Lonafarnib can be increased when it is combined with Ritonavir.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Ritonavir.]
[J05AJ04, cabotegravir, The metabolism of Cabotegravir can be increased when combined with Ritonavir.]
[L04AD03, voclosporin, The metabolism of Voclosporin can be decreased when combined with Ritonavir.]
[P03AX07, abametapir, The serum concentration of Ritonavir can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Ritonavir.]
[V03AF12, trilaciclib, Ritonavir may decrease the excretion rate of Trilaciclib which could result in a higher serum level.]
[N03AX10, felbamate, The serum concentration of Felbamate can be increased when it is combined with Ritonavir.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be increased when combined with Ritonavir.]
[G04CB01, finasteride, The serum concentration of Finasteride can be increased when it is combined with Ritonavir.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Flumequine.]
[R03BA03, flunisolide, The serum concentration of Flunisolide can be increased when it is combined with Ritonavir.]
[S02BA08, fluocinolone acetonide, The serum concentration of Fluocinolone acetonide can be increased when it is combined with Ritonavir.]
[S01JA01, fluorescein, Ritonavir may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Ritonavir.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Ritonavir.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Ritonavir.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The metabolism of Ritonavir can be decreased when combined with Peginterferon alfa-2b.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ritonavir.]
[A02BA01, cimetidine, The metabolism of Ritonavir can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The serum concentration of Cinnarizine can be increased when it is combined with Ritonavir.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Ritonavir can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Ritonavir.]
[S03AA07, ciprofloxacin, The metabolism of Ritonavir can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, Ritonavir may increase the QTc-prolonging activities of Citalopram.]
[J02AX07, ibrexafungerp, The serum concentration of Ibrexafungerp can be increased when it is combined with Ritonavir.]
[C03DA05, finerenone, The serum concentration of the active metabolites of Finerenone can be increased when Finerenone is used in combination with Ritonavir.]
[L04AA48, belumosudil, The serum concentration of Belumosudil can be increased when it is combined with Ritonavir.]
[P01CA03, fexinidazole, The serum concentration of Fexinidazole can be increased when it is combined with Ritonavir.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Ritonavir.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Mobocertinib.]
[L01FX23, tisotumab vedotin, The serum concentration of Tisotumab vedotin can be increased when it is combined with Ritonavir.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Ritonavir.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ritonavir.]
[L04AA59, avacopan, The serum concentration of Avacopan can be increased when it is combined with Ritonavir.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be increased when combined with Ritonavir.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ritonavir.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Ritonavir.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Ritonavir.]
[N06AX25, St. John's wort extract, The serum concentration of Ritonavir can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Asciminib can be increased when it is combined with Ritonavir.]
[L02BG06, exemestane, The serum concentration of Exemestane can be increased when it is combined with Ritonavir.]
[J05AX10, maribavir, The serum concentration of Maribavir can be increased when it is combined with Ritonavir.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Ritonavir can be decreased when combined with Ropeginterferon alfa-2b.]
[D07AD01, clobetasol, The serum concentration of Clobetasol can be increased when it is combined with Ritonavir.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Ritonavir.]
[J04BA01, clofazimine, Clofazimine may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[C10AB01, clofibrate, The serum concentration of Clofibrate can be increased when it is combined with Ritonavir.]
[B06AX04, mitapivat, The metabolism of Mitapivat can be decreased when combined with Ritonavir.]
[N01BB10, levobupivacaine, The serum concentration of Levobupivacaine can be increased when it is combined with Ritonavir.]
[L01EJ03, pacritinib, The serum concentration of Pacritinib can be increased when it is combined with Ritonavir.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Ritonavir.]
[N06AA04, clomipramine, The serum concentration of Clomipramine can be increased when it is combined with Ritonavir.]
[N03AE01, clonazepam, The serum concentration of Clonazepam can be increased when it is combined with Ritonavir.]
[S01EA04, clonidine, The serum concentration of Clonidine can be increased when it is combined with Ritonavir.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Ritonavir.]
[C01EB24, mavacamten, The serum concentration of Mavacamten can be increased when it is combined with Ritonavir.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Ritonavir.]
[J02AC06, oteseconazole, The serum concentration of Ritonavir can be increased when it is combined with Oteseconazole.]
[A02BC08, vonoprazan, The serum concentration of Vonoprazan can be increased when it is combined with Ritonavir.]
[A16AX21, elivaldogene autotemcel, The therapeutic efficacy of Elivaldogene autotemcel can be decreased when used in combination with Ritonavir.]
[A05BA08, glycyrrhizic acid, Ritonavir may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[N05BA21, clotiazepam, The serum concentration of Clotiazepam can be increased when it is combined with Ritonavir.]
[A04AA01, ondansetron, The serum concentration of Ondansetron can be increased when it is combined with Ritonavir.]
[A04AA02, granisetron, The serum concentration of Granisetron can be increased when it is combined with Ritonavir.]
[J05AX31, lenacapavir, The metabolism of Lenacapavir can be increased when combined with Ritonavir.]
[L01XX77, adagrasib, The serum concentration of Adagrasib can be increased when it is combined with Ritonavir.]
[N05AH02, clozapine, The serum concentration of Clozapine can be increased when it is combined with Ritonavir.]
[L01EN04, futibatinib, The metabolism of Futibatinib can be decreased when combined with Ritonavir.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Ritonavir.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Ritonavir.]
[H01AC08, somatrogon, The metabolism of Ritonavir can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The serum concentration of Cocaine can be increased when it is combined with Ritonavir.]
[M09AX11, palovarotene, The serum concentration of Palovarotene can be increased when it is combined with Ritonavir.]
[L04AC21, bimekizumab, The metabolism of Ritonavir can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The serum concentration of Codeine can be increased when it is combined with Ritonavir.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Ritonavir.]
[L04AA13, leflunomide, Ritonavir may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Desflurane.]
[A10BX03, nateglinide, The serum concentration of Nateglinide can be increased when it is combined with Ritonavir.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Ritonavir.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ritonavir.]
[J01FA15, telithromycin, The serum concentration of Telithromycin can be increased when it is combined with Ritonavir.]
[R03BA08, ciclesonide, The serum concentration of Ciclesonide can be increased when it is combined with Ritonavir.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Desloratadine.]
[M01AH03, valdecoxib, The serum concentration of Valdecoxib can be increased when it is combined with Ritonavir.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Ritonavir.]
[M01AH04, parecoxib, The serum concentration of Parecoxib can be increased when it is combined with Ritonavir.]
[J02AC02, itraconazole, The serum concentration of Itraconazole can be increased when it is combined with Ritonavir.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be increased when combined with Ritonavir.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Emedastine.]
[N05BA10, ketazolam, The serum concentration of Ketazolam can be increased when it is combined with Ritonavir.]
[L02BA03, fulvestrant, The metabolism of Fulvestrant can be increased when combined with Ritonavir.]
[L01EA01, imatinib, The serum concentration of Imatinib can be increased when it is combined with Ritonavir.]
[J02AC04, posaconazole, The serum concentration of Posaconazole can be increased when it is combined with Ritonavir.]
[A02BC05, esomeprazole, The serum concentration of Esomeprazole can be increased when it is combined with Ritonavir.]
[C08CA09, lacidipine, The serum concentration of Lacidipine can be increased when it is combined with Ritonavir.]
[N03AX09, lamotrigine, The serum concentration of Lamotrigine can be decreased when it is combined with Ritonavir.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Levocabastine.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Nafarelin.]
[S01BA03, cortisone, The metabolism of Cortisone can be decreased when combined with Ritonavir.]
[N07BC04, lofexidine, The metabolism of Lofexidine can be decreased when combined with Ritonavir.]
[S01AE04, lomefloxacin, The metabolism of Lomefloxacin can be increased when combined with Ritonavir.]
[R06AX13, loratadine, The serum concentration of Loratadine can be increased when it is combined with Ritonavir.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA11, manidipine, The serum concentration of Manidipine can be increased when it is combined with Ritonavir.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Mebeverine.]
[S01BA08, medrysone, The serum concentration of Medrysone can be increased when it is combined with Ritonavir.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Ritonavir.]
[H02AB15, meprednisone, The serum concentration of Meprednisone can be increased when it is combined with Ritonavir.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Ritonavir.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Adenosine.]
[C04AX01, cyclandelate, The serum concentration of Cyclandelate can be increased when it is combined with Ritonavir.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Cyclizine.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be decreased when combined with Ritonavir.]
[N05AD03, metylperon, The metabolism of Ritonavir can be decreased when combined with Melperone.]
[J01FA03, midecamycin, The serum concentration of Midecamycin can be increased when it is combined with Ritonavir.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Ritonavir.]
[J05AF07, tenofovir disoproxil, The risk or severity of adverse effects can be increased when Ritonavir is combined with Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Ritonavir.]
[N06AX07, minaprine, The metabolism of Minaprine can be decreased when combined with Ritonavir.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be increased when it is combined with Ritonavir.]
[N06AG02, moclobemide, The metabolism of Moclobemide can be decreased when combined with Ritonavir.]
[N06BA07, modafinil, The metabolism of Ritonavir can be increased when combined with Armodafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Ritonavir.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Moexipril.]
[C10AA07, rosuvastatin, The serum concentration of Rosuvastatin can be increased when it is combined with Ritonavir.]
[C03XA02, conivaptan, The serum concentration of Conivaptan can be increased when it is combined with Ritonavir.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Cytarabine.]
[J05AF10, entecavir, The metabolism of Entecavir can be increased when combined with Ritonavir.]
[G04BE09, vardenafil, The serum concentration of Vardenafil can be increased when it is combined with Ritonavir.]
[M01AH05, etoricoxib, The serum concentration of Etoricoxib can be increased when it is combined with Ritonavir.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be increased when combined with Ritonavir.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Ritonavir.]
[G03XA01, danazol, The metabolism of Ritonavir can be decreased when combined with Danazol.]
[J04BA02, dapsone, The serum concentration of Dapsone can be increased when it is combined with Ritonavir.]
[L01DB02, daunorubicin, Ritonavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Ritonavir.]
[G03XX01, prasterone, The serum concentration of Prasterone can be increased when it is combined with Ritonavir.]
[A04AD11, nabilone, The serum concentration of Nabilone can be increased when it is combined with Ritonavir.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be increased when combined with Ritonavir.]
[C07AB12, nebivolol, The serum concentration of Nebivolol can be increased when it is combined with Ritonavir.]
[N06AX06, nefazodone, The serum concentration of Nefazodone can be increased when it is combined with Ritonavir.]
[L02BB02, nilutamide, The metabolism of Nilutamide can be decreased when combined with Ritonavir.]
[N03AG06, tiagabine, The serum concentration of Tiagabine can be increased when it is combined with Ritonavir.]
[G03DB04, nomegestrol, The serum concentration of Nomegestrol can be decreased when it is combined with Ritonavir.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be increased when combined with Ritonavir.]
[D11AH02, pimecrolimus, The serum concentration of Pimecrolimus can be increased when it is combined with Ritonavir.]
[N06AB10, escitalopram, The serum concentration of Ritonavir can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The serum concentration of Solifenacin can be increased when it is combined with Ritonavir.]
[N06AA01, desipramine, The metabolism of Desipramine can be decreased when combined with Ritonavir.]
[S01BA11, desonide, The serum concentration of Desonide can be increased when it is combined with Ritonavir.]
[C09XA02, aliskiren, The serum concentration of Aliskiren can be increased when it is combined with Ritonavir.]
[L01XA03, oxaliplatin, Ritonavir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[N03AF02, oxcarbazepine, The metabolism of Ritonavir can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The serum concentration of Dexamethasone can be increased when it is combined with Ritonavir.]
[G04BD04, oxybutynin, The serum concentration of Oxybutynin can be increased when it is combined with Ritonavir.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Ritonavir.]
[L04AB04, adalimumab, The metabolism of Ritonavir can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The serum concentration of Gefitinib can be increased when it is combined with Ritonavir.]
[N06BA02, dextroamphetamine, The metabolism of Amphetamine can be decreased when combined with Ritonavir.]
[R05DA09, dextromethorphan, The serum concentration of Dextromethorphan can be increased when it is combined with Ritonavir.]
[N03AC01, paramethadione, The serum concentration of Paramethadione can be increased when it is combined with Ritonavir.]
[N06AB05, paroxetine, The serum concentration of Paroxetine can be increased when it is combined with Ritonavir.]
[B01AC04, clopidogrel, The serum concentration of Clopidogrel can be increased when it is combined with Ritonavir.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be increased when combined with Ritonavir.]
[N05BA01, diazepam, The serum concentration of Diazepam can be increased when it is combined with Ritonavir.]
[S01BC03, diclofenac, The serum concentration of Diclofenac can be increased when it is combined with Ritonavir.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Foscarnet.]
[G03CC02, dienestrol, The risk or severity of liver enzyme elevations can be increased when Dienestrol is combined with Ritonavir.]
[C02DG01, pinacidil, The serum concentration of Pinacidil can be increased when it is combined with Ritonavir.]
[A03AX04, pinaverium, The serum concentration of Pinaverium can be increased when it is combined with Ritonavir.]
[A10BG03, pioglitazone, The serum concentration of Pioglitazone can be increased when it is combined with Ritonavir.]
[L01DC04, ixabepilone, The serum concentration of Ixabepilone can be increased when it is combined with Ritonavir.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Ritonavir.]
[L02AA01, diethylstilbestrol, The serum concentration of Diethylstilbestrol can be decreased when it is combined with Ritonavir.]
[C08CA03, isradipine, The serum concentration of Isradipine can be increased when it is combined with Ritonavir.]
[D07XC04, diflucortolone, The serum concentration of Difluocortolone can be increased when it is combined with Ritonavir.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Ritonavir.]
[C01AA05, digoxin, The bioavailability of Digoxin can be increased when combined with Ritonavir.]
[C02DB01, dihydralazine, The metabolism of Dihydralazine can be increased when combined with Ritonavir.]
[L02AA02, polyestradiol phosphate, The risk or severity of liver enzyme elevations can be increased when Polyestradiol phosphate is combined with Ritonavir.]
[C10AX09, ezetimibe, The metabolism of Ezetimibe can be increased when combined with Ritonavir.]
[C04AE04, dihydroergocristine, The serum concentration of Dihydroergocristine can be increased when it is combined with Ritonavir.]
[N02CA01, dihydroergotamine, The serum concentration of Dihydroergotamine can be increased when it is combined with Ritonavir.]
[N02AA03, hydromorphone, The metabolism of Hydromorphone can be decreased when combined with Ritonavir.]
[B01AC21, treprostinil, The serum concentration of Treprostinil can be increased when it is combined with Ritonavir.]
[D07AC18, prednicarbate, The serum concentration of Prednicarbate can be increased when it is combined with Ritonavir.]
[C08DB01, diltiazem, The serum concentration of Diltiazem can be increased when it is combined with Ritonavir.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Dimenhydrinate.]
[M02AX03, dimethyl sulfoxide, The metabolism of Ritonavir can be decreased when combined with Dimethyl sulfoxide.]
[G03CA09, promestriene, The risk or severity of liver enzyme elevations can be increased when Promestriene is combined with Ritonavir.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be increased when combined with Ritonavir.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Ritonavir.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be increased when combined with Ritonavir.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be decreased when combined with Ritonavir.]
[N05CD10, quazepam, The serum concentration of Quazepam can be increased when it is combined with Ritonavir.]
[B01AC07, dipyridamole, The serum concentration of Dipyridamole can be increased when it is combined with Ritonavir.]
[A03FA02, cisapride, The serum concentration of Cisapride can be increased when it is combined with Ritonavir.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Ritonavir.]
[N05AL04, remoxipride, The metabolism of Remoxipride can be decreased when combined with Ritonavir.]
[C01BA03, disopyramide, The serum concentration of Disopyramide can be increased when it is combined with Ritonavir.]
[P03AA04, disulfiram, The risk or severity of adverse effects can be increased when Ritonavir is combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Ritonavir can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The serum concentration of Ritonavir can be decreased when it is combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Ritonavir.]
[N07XX02, riluzole, Ritonavir may decrease the excretion rate of Riluzole which could result in a higher serum level.]
[N05AX08, risperidone, The serum concentration of Risperidone can be increased when it is combined with Ritonavir.]
[R06AE09, levocetirizine, The serum concentration of Levocetirizine can be increased when it is combined with Ritonavir.]
[N01BB09, ropivacaine, The metabolism of Ropivacaine can be increased when combined with Ritonavir.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Rosoxacin.]
[L01EX01, sunitinib, The serum concentration of Sunitinib can be increased when it is combined with Ritonavir.]
[A04AD12, aprepitant, The serum concentration of Aprepitant can be increased when it is combined with Ritonavir.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Ritonavir.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Ritonavir.]
[J05AE07, fosamprenavir, The serum concentration of amprenavir, an active metabolite of Fosamprenavir, can be increased when used in combination with Ritonavir.]
[G04BE08, tadalafil, The serum concentration of Tadalafil can be increased when it is combined with Ritonavir.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Ritonavir.]
[C02KX02, ambrisentan, The serum concentration of Ambrisentan can be increased when it is combined with Ritonavir.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Ritonavir.]
[R03AC12, salmeterol, The metabolism of Salmeterol can be decreased when combined with Ritonavir.]
[A03FA03, domperidone, The serum concentration of Domperidone can be increased when it is combined with Ritonavir.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Ritonavir.]
[N06AA12, doxepin, The serum concentration of Doxepin can be increased when it is combined with Ritonavir.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Ritonavir.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ritonavir.]
[N06AB06, sertraline, The serum concentration of Sertraline can be increased when it is combined with Ritonavir.]
[N01AB08, sevoflurane, The serum concentration of Sevoflurane can be increased when it is combined with Ritonavir.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Droperidol.]
[A08AA10, sibutramine, The serum concentration of Sibutramine can be increased when it is combined with Ritonavir.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Ritonavir.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03DB01, dydrogesterone, The serum concentration of Dydrogesterone can be increased when it is combined with Ritonavir.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Sultopride.]
[N02CC01, sumatriptan, Ritonavir may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[C07AB13, talinolol, The metabolism of Talinolol can be decreased when combined with Ritonavir.]
[H01AA01, corticotropin, The serum concentration of Corticotropin can be increased when it is combined with Ritonavir.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Temafloxacin.]
[M01AC02, tenoxicam, The metabolism of Tenoxicam can be increased when combined with Ritonavir.]
[D01BA02, terbinafine, The serum concentration of Terbinafine can be increased when it is combined with Ritonavir.]
[G04BD05, terodiline, The serum concentration of Terodiline can be increased when it is combined with Ritonavir.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Ritonavir.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Emetine.]
[N06AX14, tianeptine, The serum concentration of Tianeptine can be increased when it is combined with Ritonavir.]
[G03CX01, tibolone, The risk or severity of liver enzyme elevations can be increased when Tibolone is combined with Ritonavir.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Enalapril.]
[M01AG02, tolfenamic acid, The serum concentration of Tolfenamic acid can be increased when it is combined with Ritonavir.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Ritonavir.]
[L02BA02, toremifene, The serum concentration of Toremifene can be increased when it is combined with Ritonavir.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Ritonavir.]
[H02CA01, trilostane, The metabolism of Trilostane can be decreased when combined with Ritonavir.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Triptorelin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Ritonavir.]
[L01CA04, vinorelbine, The serum concentration of Vinorelbine can be increased when it is combined with Ritonavir.]
[S01GX10, epinastine, The serum concentration of Epinastine can be increased when it is combined with Ritonavir.]
[N06AX16, venlafaxine, The serum concentration of Venlafaxine can be increased when it is combined with Ritonavir.]
[C08CA12, mepirodipine, The metabolism of Barnidipine can be decreased when combined with Ritonavir.]
[N05CF02, zolpidem, The serum concentration of Zolpidem can be increased when it is combined with Ritonavir.]
[M01AB04, zomepirac, The serum concentration of Zomepirac can be increased when it is combined with Ritonavir.]
[N03AX15, zonisamide, The serum concentration of Zonisamide can be increased when it is combined with Ritonavir.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Ritonavir.]
[N05CF01, zopiclone, The serum concentration of Zopiclone can be increased when it is combined with Ritonavir.]
[N05AX11, zotepine, The serum concentration of Zotepine can be increased when it is combined with Ritonavir.]
[C02AC02, guanfacine, The metabolism of Guanfacine can be decreased when combined with Ritonavir.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Moricizine.]
[G02AB03, ergonovine, The serum concentration of Ergometrine can be increased when it is combined with Ritonavir.]
[C04AE01, ergoloid mesylates, USP, The serum concentration of Ergoloid mesylate can be increased when it is combined with Ritonavir.]
[N02CA02, ergotamine, The serum concentration of Ergotamine can be increased when it is combined with Ritonavir.]
[N03AG01, valproic acid, The metabolism of Valproic acid can be increased when combined with Ritonavir.]
[S01AA17, erythromycin, The serum concentration of Erythromycin can be increased when it is combined with Ritonavir.]
[N05CD04, estazolam, The serum concentration of Estazolam can be increased when it is combined with Ritonavir.]
[A02BC02, pantoprazole, The serum concentration of Pantoprazole can be increased when it is combined with Ritonavir.]
[H05BX01, cinacalcet, The serum concentration of Cinacalcet can be increased when it is combined with Ritonavir.]
[G03CA03, estradiol, The serum concentration of Estradiol can be decreased when it is combined with Ritonavir.]
[L01XX11, estramustine, The serum concentration of Estramustine can be increased when it is combined with Ritonavir.]
[G03CC06, estriol, The risk or severity of liver enzyme elevations can be increased when Estriol is combined with Ritonavir.]
[G03CA57, estrogens, conjugated (USP), The serum concentration of Conjugated estrogens can be increased when it is combined with Ritonavir.]
[G03CC04, estrone, The risk or severity of liver enzyme elevations can be increased when Estrone is combined with Ritonavir.]
[J04AK02, ethambutol, The metabolism of Ritonavir can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The serum concentration of Fluticasone furoate can be increased when it is combined with Ritonavir.]
[R03BA05, fluticasone, The serum concentration of Fluticasone can be increased when it is combined with Ritonavir.]
[C10AA04, fluvastatin, The serum concentration of Fluvastatin can be increased when it is combined with Ritonavir.]
[L02AA03, ethinyl estradiol, The serum concentration of Ethinylestradiol can be decreased when it is combined with Ritonavir.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Ibutilide.]
[N03AD01, ethosuximide, The serum concentration of Ethosuximide can be increased when it is combined with Ritonavir.]
[M01AC06, meloxicam, The serum concentration of Meloxicam can be increased when it is combined with Ritonavir.]
[S01XA06, ethylmorphine, The serum concentration of Ethylmorphine can be increased when it is combined with Ritonavir.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Ritonavir.]
[N05AE03, sertindole, The serum concentration of Sertindole can be increased when it is combined with Ritonavir.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Ajmaline.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Ritonavir.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Nizatidine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Fleroxacin.]
[R06AX11, astemizole, The serum concentration of Astemizole can be increased when it is combined with Ritonavir.]
[R06AX12, terfenadine, The serum concentration of Terfenadine can be increased when it is combined with Ritonavir.]
[N06AX12, bupropion, The metabolism of Bupropion can be increased when combined with Ritonavir.]
[N06AB08, fluvoxamine, The serum concentration of Fluvoxamine can be increased when it is combined with Ritonavir.]
[C01BB03, tocainide, The metabolism of Tocainide can be increased when combined with Ritonavir.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Ritonavir.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ritonavir.]
[C10AA03, pravastatin, Ritonavir may increase the myopathic rhabdomyolysis activities of Pravastatin.]
[A05AA01, chenodeoxycholic acid, The serum concentration of Chenodeoxycholic acid can be increased when it is combined with Ritonavir.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Ritonavir which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Famotidine.]
[P02CA03, albendazole, The serum concentration of Albendazole can be increased when it is combined with Ritonavir.]
[C08CA02, felodipine, The serum concentration of Felodipine can be increased when it is combined with Ritonavir.]
[C08EA01, fendiline, The serum concentration of Fendiline can be increased when it is combined with Ritonavir.]
[N03AX26, fenfluramine, The metabolism of Fenfluramine can be decreased when combined with Ritonavir.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Ritonavir.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Salbutamol.]
[L01BB06, clofarabine, Ritonavir may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[L04AA40, cladribine, Ritonavir may decrease the excretion rate of Cladribine which could result in a higher serum level.]
[N07AX03, cevimeline, The serum concentration of Cevimeline can be increased when it is combined with Ritonavir.]
[C01BC04, flecainide, The serum concentration of Flecainide can be increased when it is combined with Ritonavir.]
[J01CF05, floxacillin, Flucloxacillin may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[J02AC01, fluconazole, The metabolism of Ritonavir can be decreased when combined with Fluconazole.]
[H02AA02, fludrocortisone, The serum concentration of Fludrocortisone can be increased when it is combined with Ritonavir.]
[D07XB01, flumethasone, The serum concentration of Flumethasone can be increased when it is combined with Ritonavir.]
[N07CA03, flunarizine, The serum concentration of Flunarizine can be increased when it is combined with Ritonavir.]
[N05CD03, flunitrazepam, The serum concentration of Flunitrazepam can be increased when it is combined with Ritonavir.]
[D07AC08, fluocinonide, The serum concentration of Fluocinonide can be increased when it is combined with Ritonavir.]
[H02AB03, fluocortolone, The serum concentration of Fluocortolone can be increased when it is combined with Ritonavir.]
[V03AZ01, ethanol, The serum concentration of Ethanol can be increased when it is combined with Ritonavir.]
[S01CB05, fluorometholone, The serum concentration of Fluorometholone can be increased when it is combined with Ritonavir.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Ritonavir.]
[N06AB03, fluoxetine, The serum concentration of Ritonavir can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Flupentixol.]
[N05AB02, fluphenazine, The metabolism of Ritonavir can be decreased when combined with Fluphenazine.]
[D07AC07, flurandrenolide, The serum concentration of Flurandrenolide can be increased when it is combined with Ritonavir.]
[N05CD01, flurazepam, The serum concentration of Flurazepam can be increased when it is combined with Ritonavir.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be increased when combined with Ritonavir.]
[N05AG01, fluspirilene, The serum concentration of Fluspirilene can be increased when it is combined with Ritonavir.]
[L02BB01, flutamide, The serum concentration of Flutamide can be increased when it is combined with Ritonavir.]
[V04CX02, folic acid, Ritonavir may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Ritonavir.]
[C03CA01, furosemide, The metabolism of Furosemide can be increased when combined with Ritonavir.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Alendronic acid.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be increased when it is combined with Ritonavir.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Amisulpride.]
[N06DA04, galantamine, The serum concentration of Galantamine can be increased when it is combined with Ritonavir.]
[C08DA02, gallopamil, The serum concentration of Gallopamil can be increased when it is combined with Ritonavir.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Ganciclovir.]
[C10AB04, gemfibrozil, The serum concentration of Gemfibrozil can be increased when it is combined with Ritonavir.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Degarelix.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Ritonavir.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Ritonavir.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be increased when combined with Ritonavir.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Ritonavir.]
[J05AG04, etravirine, The serum concentration of Etravirine can be decreased when it is combined with Ritonavir.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Methsuximide.]
[G03XA02, gestrinone, The serum concentration of Gestrinone can be decreased when it is combined with Ritonavir.]
[N01AH02, alfentanil, Ritonavir may decrease the excretion rate of Alfentanil which could result in a higher serum level.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Ritonavir.]
[A10BB01, glyburide, The serum concentration of Glyburide can be increased when it is combined with Ritonavir.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Ritonavir.]
[A10BB07, glipizide, The metabolism of Glipizide can be increased when combined with Ritonavir.]
[N05CM18, dexmedetomidine, The metabolism of Ritonavir can be decreased when combined with Dexmedetomidine.]
[C01BD04, dofetilide, The serum concentration of Dofetilide can be increased when it is combined with Ritonavir.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Ritonavir.]
[L01EX02, sorafenib, The serum concentration of Sorafenib can be increased when it is combined with Ritonavir.]
[C07AB09, esmolol, The metabolism of Esmolol can be decreased when combined with Ritonavir.]
[B01AA12, fluindione, The metabolism of Fluindione can be increased when combined with Ritonavir.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Goserelin.]
[P01BX01, halofantrine, The serum concentration of Halofantrine can be increased when it is combined with Ritonavir.]
[D07AD02, halcinonide, The serum concentration of Halcinonide can be increased when it is combined with Ritonavir.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Ritonavir.]
[N01AB01, halothane, The serum concentration of Halothane can be increased when it is combined with Ritonavir.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Histrelin.]
[N05AH04, quetiapine, The serum concentration of Quetiapine can be increased when it is combined with Ritonavir.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Ritonavir.]
[L01CE02, irinotecan, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Ritonavir.]
[M04AA01, allopurinol, Ritonavir may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The serum concentration of Losartan can be increased when it is combined with Ritonavir.]
[G03DC01, allylestrenol, The serum concentration of Allylestrenol can be increased when it is combined with Ritonavir.]
[A07EC02, mesalamine, The excretion of Mesalazine can be decreased when combined with Ritonavir.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Ritonavir.]
[J05AG01, nevirapine, The serum concentration of Nevirapine can be increased when it is combined with Ritonavir.]
[C08CA10, nilvadipine, The serum concentration of Nilvadipine can be increased when it is combined with Ritonavir.]
[M02AA26, nimesulide, The serum concentration of Nimesulide can be increased when it is combined with Ritonavir.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, The metabolism of Hydrocodone can be decreased when combined with Ritonavir.]
[S02BA01, hydrocortisone, The serum concentration of Hydrocortisone can be increased when it is combined with Ritonavir.]
[D07AC16, hydrocortisone aceponate, The serum concentration of Hydrocortisone aceponate can be increased when it is combined with Ritonavir.]
[D07AB02, hydrocortisone butyrate, The serum concentration of Hydrocortisone butyrate can be increased when it is combined with Ritonavir.]
[D07AB11, hydrocortisone probutate, The serum concentration of Hydrocortisone probutate can be increased when it is combined with Ritonavir.]
[G04BD06, propiverine, The serum concentration of Propiverine can be increased when it is combined with Ritonavir.]
[P01BA02, hydroxychloroquine, The serum concentration of Hydroxychloroquine can be increased when it is combined with Ritonavir.]
[G03DA03, 17-alpha-hydroxyprogesterone, The serum concentration of Hydroxyprogesterone can be increased when it is combined with Ritonavir.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Hydroxyzine.]
[J04AB04, rifabutin, The serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Ritonavir.]
[S01BA13, rimexolone, The serum concentration of Rimexolone can be increased when it is combined with Ritonavir.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Risedronic acid.]
[R02AX02, ibuprofen, The serum concentration of Ibuprofen can be increased when it is combined with Ritonavir.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Ritonavir.]
[L01AA06, ifosfamide, The serum concentration of Ifosfamide can be increased when it is combined with Ritonavir.]
[N01AH03, sufentanil, Ritonavir may decrease the excretion rate of Sufentanil which could result in a higher serum level.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Ritonavir.]
[L01CD01, paclitaxel, The serum concentration of Paclitaxel can be increased when it is combined with Ritonavir.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Terlipressin.]
[M03BX02, tizanidine, The metabolism of Tizanidine can be increased when combined with Ritonavir.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Ritonavir.]
[C03BA11, indapamide, The serum concentration of Indapamide can be increased when it is combined with Ritonavir.]
[S01BC01, indomethacin, The metabolism of Indomethacin can be increased when combined with Ritonavir.]
[N06AX17, milnacipran, The serum concentration of Milnacipran can be increased when it is combined with Ritonavir.]
[A10BH01, sitagliptin, The serum concentration of Sitagliptin can be increased when it is combined with Ritonavir.]
[N05BA12, alprazolam, The serum concentration of Alprazolam can be increased when it is combined with Ritonavir.]
[N05CH02, ramelteon, The serum concentration of Ramelteon can be increased when it is combined with Ritonavir.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Ritonavir.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ritonavir.]
[C10AA06, cerivastatin, The serum concentration of Cerivastatin can be increased when it is combined with Ritonavir.]
[L01XX35, anagrelide, The metabolism of Anagrelide can be increased when combined with Ritonavir.]
[C07AA01, alprenolol, The metabolism of Alprenolol can be decreased when combined with Ritonavir.]
[V03AB01, ipecac, The serum concentration of Ipecac can be increased when it is combined with Ritonavir.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Stavudine.]
[N06AF05, iproniazid, The metabolism of Ritonavir can be decreased when combined with Iproniazid.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be increased when combined with Ritonavir.]
[D06BB10, imiquimod, The serum concentration of Imiquimod can be increased when it is combined with Ritonavir.]
[P01AX06, atovaquone, The serum concentration of Atovaquone can be decreased when it is combined with Ritonavir.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Isoflurane.]
[N04BX02, entacapone, The metabolism of Ritonavir can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Ritonavir can be decreased when combined with Isoniazid.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Ritonavir.]
[D10BA01, isotretinoin, The serum concentration of Isotretinoin can be increased when it is combined with Ritonavir.]
[P02CF01, ivermectin, The serum concentration of Ivermectin can be increased when it is combined with Ritonavir.]
[N06AX18, reboxetine, The serum concentration of Reboxetine can be increased when it is combined with Ritonavir.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Ritonavir.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC07, tocilizumab, The metabolism of Ritonavir can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The serum concentration of Ketamine can be increased when it is combined with Ritonavir.]
[B01AC22, prasugrel, The serum concentration of Prasugrel can be increased when it is combined with Ritonavir.]
[J02AB02, ketoconazole, The bioavailability of Ketoconazole can be increased when combined with Ritonavir.]
[H02CA04, levoketoconazole, The serum concentration of Levoketoconazole can be increased when it is combined with Ritonavir.]
[N05AH03, olanzapine, The metabolism of Olanzapine can be decreased when combined with Ritonavir.]
[M02AA10, ketoprofen, The metabolism of Ketoprofen can be increased when combined with Ritonavir.]
[V03AC03, deferasirox, The metabolism of Deferasirox can be increased when combined with Ritonavir.]
[L04AA24, abatacept, The metabolism of Ritonavir can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Mizolastine.]
[N04BC09, rotigotine, The serum concentration of Rotigotine can be increased when it is combined with Ritonavir.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Nalidixic acid.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Ritonavir.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Amantadine.]
[J05AX09, maraviroc, The metabolism of Maraviroc can be decreased when combined with Ritonavir.]
[N03AX18, lacosamide, The serum concentration of Lacosamide can be increased when it is combined with Ritonavir.]
[A05AA02, ursodiol, Ursodeoxycholic acid may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[R05CB06, ambroxol, The serum concentration of Ambroxol can be increased when it is combined with Ritonavir.]
[G03AD01, levonorgestrel, The serum concentration of Levonorgestrel can be decreased when it is combined with Ritonavir.]
[S02DA01, lidocaine, The serum concentration of Lidocaine can be increased when it is combined with Ritonavir.]
[C08EX01, lidoflazine, The serum concentration of Lidoflazine can be increased when it is combined with Ritonavir.]
[N06BA13, armodafinil, The metabolism of Ritonavir can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Ritonavir.]
[N02CA07, lisuride, The serum concentration of Lisuride can be increased when it is combined with Ritonavir.]
[A07DA03, loperamide, The serum concentration of Loperamide can be increased when it is combined with Ritonavir.]
[N05BA06, lorazepam, The serum concentration of Lorazepam can be increased when it is combined with Ritonavir.]
[C10AA02, lovastatin, The serum concentration of Lovastatin can be increased when it is combined with Ritonavir.]
[G03DC03, lynestrenol, The serum concentration of Lynestrenol can be decreased when it is combined with Ritonavir.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be increased when it is combined with Ritonavir.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01BA05, pralatrexate, Ritonavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be decreased when combined with Ritonavir.]
[V04CX04, mannitol, The serum concentration of Mannitol can be increased when it is combined with Ritonavir.]
[N06AA21, maprotiline, The metabolism of Maprotiline can be decreased when combined with Ritonavir.]
[R06AE05, meclizine, The metabolism of Meclizine can be decreased when combined with Ritonavir.]
[C01AA08, medigoxin, The bioavailability of Metildigoxin can be increased when combined with Ritonavir.]
[G03DB03, medrogestone, The serum concentration of Medrogestone can be increased when it is combined with Ritonavir.]
[P01BC02, mefloquine, The serum concentration of Mefloquine can be increased when it is combined with Ritonavir.]
[N05CH01, melatonin, The metabolism of Melatonin can be increased when combined with Ritonavir.]
[N02AB02, meperidine, The serum concentration of normeperidine, an active metabolite of Meperidine, can be increased when used in combination with Ritonavir.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Ritonavir.]
[N03AA01, mephobarbital, The metabolism of Methylphenobarbital can be decreased when combined with Ritonavir.]
[N05AC03, mesoridazine, The metabolism of Mesoridazine can be decreased when combined with Ritonavir.]
[N05AX13, paliperidone, The serum concentration of Paliperidone can be increased when it is combined with Ritonavir.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Ritonavir.]
[A04AA04, dolasetron, The serum concentration of Dolasetron can be increased when it is combined with Ritonavir.]
[N07BC02, methadone, The serum concentration of Methadone can be decreased when it is combined with Ritonavir.]
[N06BA03, methamphetamine, The serum concentration of Metamfetamine can be increased when it is combined with Ritonavir.]
[A03AB07, methantheline, Methantheline can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05CM01, methaqualone, The serum concentration of Methaqualone can be increased when it is combined with Ritonavir.]
[J05AF05, lamivudine, Ritonavir may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[G02CB05, metergoline, The serum concentration of Metergoline can be increased when it is combined with Ritonavir.]
[H03BB02, methimazole, The metabolism of Ritonavir can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The metabolism of Pemetrexed can be increased when combined with Ritonavir.]
[L04AX03, methotrexate, The serum concentration of Methotrexate can be increased when it is combined with Ritonavir.]
[N05AA02, methotrimeprazine, The metabolism of Methotrimeprazine can be decreased when combined with Ritonavir.]
[N02BG09, methoxyflurane, The serum concentration of Methoxyflurane can be increased when it is combined with Ritonavir.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Methyldopa.]
[V04CG05, methylene blue, The metabolism of Methylene blue can be decreased when combined with Ritonavir.]
[G02AB01, methylergonovine, The serum concentration of Methylergometrine can be increased when it is combined with Ritonavir.]
[R03DA05, aminophylline, The serum concentration of Aminophylline can be increased when it is combined with Ritonavir.]
[H02AB04, methylprednisolone, The serum concentration of Methylprednisolone can be increased when it is combined with Ritonavir.]
[G03EK01, methyltestosterone, The serum concentration of Methyltestosterone can be increased when it is combined with Ritonavir.]
[N02CA04, methysergide, The serum concentration of Methysergide can be increased when it is combined with Ritonavir.]
[A03FA01, metoclopramide, The serum concentration of Metoclopramide can be increased when it is combined with Ritonavir.]
[C07AB02, metoprolol, The metabolism of Ritonavir can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of adverse effects can be increased when Ritonavir is combined with Metronidazole.]
[C01BB02, mexiletine, The serum concentration of Mexiletine can be increased when it is combined with Ritonavir.]
[N06AX03, mianserin, The serum concentration of Mianserin can be increased when it is combined with Ritonavir.]
[S02AA13, miconazole, The metabolism of Ritonavir can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The serum concentration of Aminophenazone can be increased when it is combined with Ritonavir.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Ritonavir.]
[G03XB01, mifepristone, The serum concentration of Mifepristone can be decreased when it is combined with Ritonavir.]
[C09CA03, valsartan, The excretion of Valsartan can be decreased when combined with Ritonavir.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Minocycline.]
[D11AX01, minoxidil, The metabolism of Minoxidil can be increased when combined with Ritonavir.]
[L01XX23, mitotane, The metabolism of Ritonavir can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, Ritonavir may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[N06BA12, lisdexamfetamine, The metabolism of Lisdexamfetamine can be decreased when combined with Ritonavir.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Ritonavir.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Ritonavir.]
[N02AA01, morphine, The serum concentration of Morphine can be increased when it is combined with Ritonavir.]
[A04AA05, palonosetron, The serum concentration of Palonosetron can be increased when it is combined with Ritonavir.]
[L04AB05, certolizumab pegol, The metabolism of Ritonavir can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Ritonavir.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Ritonavir.]
[L04AA06, mycophenolic acid, The metabolism of Mycophenolic acid can be increased when combined with Ritonavir.]
[J05AJ01, raltegravir, The metabolism of Raltegravir can be increased when combined with Ritonavir.]
[P01BA06, amodiaquine, The metabolism of Amodiaquine can be decreased when combined with Ritonavir.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Ritonavir.]
[G03XC01, raloxifene, The metabolism of Raloxifene can be increased when combined with Ritonavir.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Ritonavir.]
[N03AB05, fosphenytoin, The serum concentration of Ritonavir can be decreased when it is combined with Fosphenytoin.]
[C07AA12, nadolol, The metabolism of Nadolol can be decreased when combined with Ritonavir.]
[N04BC04, ropinirole, The metabolism of Ropinirole can be increased when combined with Ritonavir.]
[V03AB15, naloxone, The metabolism of Ritonavir can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The metabolism of Naltrexone can be increased when combined with Ritonavir.]
[L04AC03, anakinra, The metabolism of Ritonavir can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The metabolism of Amphetamine can be decreased when combined with Ritonavir.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Ritonavir.]
[A10BG01, troglitazone, The metabolism of Troglitazone can be decreased when combined with Ritonavir.]
[N06AX21, duloxetine, The metabolism of Ritonavir can be decreased when combined with Duloxetine.]
[L01CD02, docetaxel, The serum concentration of Docetaxel can be increased when it is combined with Ritonavir.]
[L02BG04, letrozole, The serum concentration of Letrozole can be increased when it is combined with Ritonavir.]
[N01AH06, remifentanil, Ritonavir may decrease the excretion rate of Remifentanil which could result in a higher serum level.]
[A10BX02, repaglinide, The serum concentration of Repaglinide can be increased when it is combined with Ritonavir.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Levosimendan.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Ritonavir.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Amphotericin B.]
[N06AX23, desvenlafaxine, The serum concentration of Desvenlafaxine can be increased when it is combined with Ritonavir.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[M04AA03, febuxostat, The excretion of Ritonavir can be decreased when combined with Febuxostat.]
[H05BX02, paricalcitol, The serum concentration of Paricalcitol can be increased when it is combined with Ritonavir.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Niacin.]
[C08CA04, nicardipine, The serum concentration of Nicardipine can be increased when it is combined with Ritonavir.]
[C04AE02, nicergoline, The serum concentration of Nicergoline can be increased when it is combined with Ritonavir.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be increased when combined with Ritonavir.]
[N07BA01, nicotine, The metabolism of Nicotine can be increased when combined with Ritonavir.]
[C08CA05, nifedipine, The serum concentration of Nifedipine can be increased when it is combined with Ritonavir.]
[C08CA06, nimodipine, The serum concentration of Nimodipine can be increased when it is combined with Ritonavir.]
[C08CA07, nisoldipine, The serum concentration of Nisoldipine can be increased when it is combined with Ritonavir.]
[N05CD02, nitrazepam, The serum concentration of Nitrazepam can be increased when it is combined with Ritonavir.]
[C08CA08, nitrendipine, The serum concentration of Nitrendipine can be increased when it is combined with Ritonavir.]
[J01XE01, nitrofurantoin, Ritonavir may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The serum concentration of Zaleplon can be increased when it is combined with Ritonavir.]
[G03DC02, norethindrone, The serum concentration of Norethisterone can be decreased when it is combined with Ritonavir.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Norfloxacin.]
[G03AC07, norgestrienone, The serum concentration of Norgestrienone can be decreased when it is combined with Ritonavir.]
[C02KX01, bosentan, The serum concentration of Bosentan can be increased when it is combined with Ritonavir.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Ritonavir.]
[G02CA02, nylidrin, The serum concentration of Nylidrin can be increased when it is combined with Ritonavir.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ritonavir.]
[S02AA16, ofloxacin, Ritonavir may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[L04AC04, rilonacept, The metabolism of Ritonavir can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The serum concentration of Omeprazole can be increased when it is combined with Ritonavir.]
[N02AA02, opium, The serum concentration of Opium can be increased when it is combined with Ritonavir.]
[G04CA02, tamsulosin, The serum concentration of Tamsulosin can be increased when it is combined with Ritonavir.]
[C01AC01, ouabain, The excretion of Ouabain can be decreased when combined with Ritonavir.]
[P02BA02, oxamniquine, The metabolism of Ritonavir can be decreased when combined with Oxamniquine.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The metabolism of Oxprenolol can be decreased when combined with Ritonavir.]
[N02AA05, oxycodone, The serum concentration of Oxycodone can be increased when it is combined with Ritonavir.]
[N02AA11, oxymorphone, The serum concentration of Oxymorphone can be increased when it is combined with Ritonavir.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ritonavir.]
[N05AH05, asenapine, The serum concentration of Asenapine can be increased when it is combined with Ritonavir.]
[G03DB06, chlormadinone, The serum concentration of Chlormadinone can be decreased when it is combined with Ritonavir.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Papaverine.]
[H02AB05, paramethasone, The serum concentration of Paramethasone can be increased when it is combined with Ritonavir.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Ritonavir.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Ritonavir.]
[C07AA23, penbutolol, The metabolism of Penbutolol can be decreased when combined with Ritonavir.]
[N05AG03, penfluridol, The serum concentration of Penfluridol can be increased when it is combined with Ritonavir.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Penicillamine.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Ritonavir.]
[N05CA01, pentobarbital, The metabolism of Ritonavir can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, The metabolism of Pentoxifylline can be increased when combined with Ritonavir.]
[N04BC02, pergolide, The serum concentration of Pergolide can be increased when it is combined with Ritonavir.]
[C08EX02, perhexiline, The serum concentration of Perhexiline can be increased when it is combined with Ritonavir.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be decreased when combined with Ritonavir.]
[N02BE03, phenacetin, The serum concentration of Phenacetin can be increased when it is combined with Ritonavir.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Ritonavir.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be increased when combined with Ritonavir.]
[B01AA04, phenprocoumon, The serum concentration of Phenprocoumon can be increased when it is combined with Ritonavir.]
[A08AA01, phentermine, The serum concentration of Phentermine can be increased when it is combined with Ritonavir.]
[M02AA01, phenylbutazone, The metabolism of Phenylbutazone can be increased when combined with Ritonavir.]
[A02BC06, dexlansoprazole, The serum concentration of Dexlansoprazole can be increased when it is combined with Ritonavir.]
[N03AB02, phenytoin, The serum concentration of Ritonavir can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Ritonavir can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Levofloxacin.]
[L02BB03, bicalutamide, The serum concentration of Bicalutamide can be increased when it is combined with Ritonavir.]
[C08CX01, mibefradil, The serum concentration of Mibefradil can be increased when it is combined with Ritonavir.]
[N05AG02, pimozide, The serum concentration of Pimozide can be increased when it is combined with Ritonavir.]
[C07AA03, pindolol, The metabolism of Pindolol can be decreased when combined with Ritonavir.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Ritonavir.]
[J05AE01, saquinavir, The serum concentration of Saquinavir can be increased when it is combined with Ritonavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Ritonavir.]
[N05AC04, pipothiazine, The serum concentration of Pipotiazine can be increased when it is combined with Ritonavir.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Eprosartan.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Ritonavir.]
[J01MA11, grepafloxacin, The serum concentration of Grepafloxacin can be increased when it is combined with Ritonavir.]
[J05AG02, delavirdine, The serum concentration of Ritonavir can be increased when it is combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Ritonavir.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be decreased when combined with Ritonavir.]
[A10BG02, rosiglitazone, The serum concentration of Rosiglitazone can be increased when it is combined with Ritonavir.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Ritonavir.]
[A03AE01, alosetron, The serum concentration of Alosetron can be increased when it is combined with Ritonavir.]
[L04AC08, canakinumab, The metabolism of Ritonavir can be increased when combined with Canakinumab.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be decreased when combined with Ritonavir.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ritonavir.]
[C10AA08, pitavastatin, The serum concentration of Pitavastatin can be decreased when it is combined with Ritonavir.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Ritonavir.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Prajmaline.]
[N05BA11, prazepam, The serum concentration of Prazepam can be increased when it is combined with Ritonavir.]
[P02BA01, praziquantel, The serum concentration of Praziquantel can be increased when it is combined with Ritonavir.]
[C02CA01, prazosin, Ritonavir may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[S03BA02, prednisolone, The serum concentration of Prednisolone can be increased when it is combined with Ritonavir.]
[H02AB07, prednisone, The serum concentration of Prednisone can be increased when it is combined with Ritonavir.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Antazoline.]
[C01DX02, prenylamine, The serum concentration of Prenylamine can be increased when it is combined with Ritonavir.]
[P01BA03, primaquine, The serum concentration of Primaquine can be increased when it is combined with Ritonavir.]
[N03AA03, primidone, The metabolism of Ritonavir can be increased when combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Probucol.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Ritonavir.]
[L01XB01, procarbazine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Procarbazine.]
[C10AB05, fenofibrate, The serum concentration of Fenofibrate can be increased when it is combined with Ritonavir.]
[N05AB04, prochlorperazine, The serum concentration of Prochlorperazine can be increased when it is combined with Ritonavir.]
[G03DA04, progesterone, The serum concentration of Progesterone can be decreased when it is combined with Ritonavir.]
[N05AA03, promazine, The serum concentration of Promazine can be increased when it is combined with Ritonavir.]
[G03DB07, promegestone, The serum concentration of Promegestone can be increased when it is combined with Ritonavir.]
[R06AD02, promethazine, The metabolism of Promethazine can be decreased when combined with Ritonavir.]
[C01BC03, propafenone, The serum concentration of Propafenone can be increased when it is combined with Ritonavir.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Ritonavir.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Ritonavir.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Ritonavir.]
[N02AC04, propoxyphene, The serum concentration of Dextropropoxyphene can be increased when it is combined with Ritonavir.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Ritonavir.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Propylthiouracil.]
[R03DC03, montelukast, The serum concentration of Montelukast can be increased when it is combined with Ritonavir.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Ritonavir.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Ritonavir.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Mepyramine.]
[P01AX05, quinacrine, The serum concentration of Quinacrine can be increased when it is combined with Ritonavir.]
[C01BA01, quinidine, The serum concentration of Quinidine can be increased when it is combined with Ritonavir.]
[P01BC01, quinine, The serum concentration of Quinine can be increased when it is combined with Ritonavir.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Ranitidine.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[J04AB02, rifampin, The serum concentration of Ritonavir can be decreased when it is combined with Rifampicin.]
[J01FA06, roxithromycin, The serum concentration of Roxithromycin can be increased when it is combined with Ritonavir.]
[A07EC01, sulfasalazine, Ritonavir may decrease the excretion rate of Sulfasalazine which could result in a higher serum level.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be increased when combined with Ritonavir.]
[S01FA02, scopolamine, The serum concentration of Scopolamine can be increased when it is combined with Ritonavir.]
[N04BD01, selegiline, The serum concentration of Selegiline can be increased when it is combined with Ritonavir.]
[V04CC03, sincalide, The excretion of Sincalide can be decreased when combined with Ritonavir.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Ritonavir.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Ritonavir.]
[C03DA01, spironolactone, Spironolactone may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[N03AF01, carbamazepine, Strong CYP3A4 inducers - protease inhibitors]
[N06AX25, St. John's wort extract, Strong CYP3A4 inducers - protease inhibitors]
[N02CA01, dihydroergotamine, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J04AB05, rifapentine, Strong CYP3A4 inducers - protease inhibitors]
[C10AA01, simvastatin, HMG Co-A reductase inhibitors - CYP3A4 inhibitors]
[G02AB03, ergonovine, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[N02CA02, ergotamine, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[L01CE02, irinotecan, Irinotecan - CYP3A4 inhibitors]
[J04AB04, rifabutin, Strong CYP3A4 inducers - protease inhibitors]
[C10AA02, lovastatin, HMG Co-A reductase inhibitors - CYP3A4 inhibitors]
[G02AB01, methylergonovine, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[C02KX01, bosentan, Strong CYP3A4 inducers - protease inhibitors]
[J04AB02, rifampin, Strong CYP3A4 inducers - protease inhibitors]
[N03AF01, carbamazepine, Strong CYP3A4 inducers - protease inhibitors]
[N06AX25, St. John's wort extract, Strong CYP3A4 inducers - protease inhibitors]
[N02CA01, dihydroergotamine, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J04AB05, rifapentine, Strong CYP3A4 inducers - protease inhibitors]
[C10AA01, simvastatin, HMG Co-A reductase inhibitors - CYP3A4 inhibitors]
[G02AB03, ergonovine, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[N02CA02, ergotamine, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[L01CE02, irinotecan, Irinotecan - CYP3A4 inhibitors]
[J04AB04, rifabutin, Strong CYP3A4 inducers - protease inhibitors]
[C10AA02, lovastatin, HMG Co-A reductase inhibitors - CYP3A4 inhibitors]
[G02AB01, methylergonovine, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[C02KX01, bosentan, Strong CYP3A4 inducers - protease inhibitors]
[J04AB02, rifampin, Strong CYP3A4 inducers - protease inhibitors]
